

**Yehuda Handelsman, MD, FACP, FNLA, FASPC, FAHA, MACE**  
Endocrinology  
Diabetes \* Metabolism \* Internal Medicine  
*Diplomate American Board Internal Medicine*

---

18372 Clark St. Suite # 212. Tarzana, CA 91356 \* Tel. 818 708 9942 \* Fax. 818-708 0154 \* E-mail: [YHandelsman@Gmail.com](mailto:YHandelsman@Gmail.com)

**Curriculum Vitae**

**Personal Information**

Date of Birth: August 22, 1947

Place of Birth: Tel Aviv, Israel

Citizenship: USA

**Current Positions**

Medical Director & Principal Investigator, Metabolic Institute of America  
Chair Scientific Advisory Board DCMi- Diabetes, CardioRenal & Metabolism Institute- a Think Tank  
Chair & Program Director, World Congress on Insulin Resistance, Diabetes & CVD  
Chair & Program director, Heart in Diabetes- initiative and Medical Congress  
Chair, DCRM Multispecialty Practice Recommendations for the management of  
diabetes, cardiorenal, and metabolic diseases  
Chair & Editor, International Lipid Forum (ILF) The LipidForum  
Member, Medical Advisory Board. 10FoldMed. Israel  
Country Chair- US, ARISE-HF, research, Applied Therapeutics AT-001-2001  
Past President, AACE, ACE & Pacific lipid Association

**Education**

Sackler Faculty of Medicine – Tel Aviv University, Tel Aviv, Israel. MD	1984
University of the Pacific – Stockton, California. B.A. Summa Cum Laude	1975
San Joaquin Delta College – Stockton, California. A.A. Highest Honors	1973

**Postdoctoral Education**

Fellowship Diabetes/Endocrinology – University of Southern California – Medical School. Los Angeles, California	1988-90
Continuing Medical Education, Internal Medicine – The College of Physicians & Surgeons of Columbia University. New York, New York	1988
Residency, Internal Medicine – New York Infirmary Beekman Downtown Hospital. Affiliate – New York University. New York City, New York	1986-88
Internship, Internal Medicine – New York Infirmary Beekman Downtown Hospital. Affiliate – New York University. New York City, New York	1985-86
Internship, Rotating – Wolfson Hospital. Hulon, Israel	1982-83

## **Present Professional Positions and Appointments**

Private Practice, – Endocrinology, Diabetes, Obesity, Metabolism, & Internal Medicine. Focus on the high-risk patient, utilizing a uniquely developed comprehensive, multiple interventions to preventing cardiovascular-kidney diseases and Heart Failure. managing Diabetes, Weight Loss, Cholesterol & Lipid Disorders, Hypertension, PCOS, Insulin Resistance-Metabolic Syndrome, Thyroid & Osteoporosis. Tarzana, California.	1991-
Metabolic Institute of America- Medical Director & Principal Investigator. Committed to Metabolic Disorders education & research- Diabetes, Lipid, HTN, Obesity, Preventive Cardiology, Thyroid & Osteoporosis. Tarzana, California	1998-
Senior Scientific & Education Consultant– “Metabolic Endocrine Education Foundation”- to improve patient’s care through education of health care professionals, the public & support clinical research. Tarzana, California.	2002-
America Clinical Trial- Principal investigator. Conducting metabolic clinical trials Such as Diabetes, Obesity, Lipid, Prevent cardiology, osteoporosis. Tarzana CA	2012
Chair Scientific Advisory Board- Diabetes, CardioRenal & Metabolism Institute- DCMi, a Thinktank	2021
Member, Board of Directors, Clinical Association of California Endocrinologists- CACE	2022
Member, Annual Program, Clinical Association of California Endocrinologists- CACE	2022
Member, Medical Advisory Board. 10FoldMed. Israel	2021
Chair, DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases	2021
Chair, The Early Intervention and Intensive Therapy in T2D & CardioRenalMetabolic Diseases- Consensus Statement. A DCMi Initiative	2022
Country Chair- US, ARISE-HF, research, Applied Therapeutics AT-001-2001	2019-
Chair, Founder, Program Director, “Annual World Congress on Insulin Resistance, diabetes & CVD” - WCIRDC	2003-
Chair, Founder & Program director, The Heart in Diabetes, initiative & Congress	2016-
Chair, Founder & Editor - International Lipid Forum The LipidForum	2013-
Chair & Founder, International Committee for Insulin Resistance	2003-
Chair & Founder, Los Angeles Forum for Diabetes & Complications	2007-
Clinical Association of California Endocrinologists- CACE, Industry Relations	2020
Clinical Association of California Endocrinologists- CACE Virtual PCP Programs	2020

Clinical Association of California Endocrinologists- CACE, Past Presidents Advisory	2020
AACE Past Presidents Council	2017
Chair, Task Force AACE Lipid Management Algorithm	2018-20
Member, AACE Comprehensive Diabetes Management Algorithm	2013-20
Member, AACE CGM/Insulin Pump Guideline	2019-21
Past-President, American College of Endocrinology	2014-15
Past President, American Association of Clinical Endocrinologists	2011-12
Past, President, Pacific Lipid Association	2018-19
Past member Board of Directors, American Association for Preventive cardiology	2016-19
Member, Advisory Board, DNATIX, the genetic blockchain company – digital genetics service provider, Israel	2018
Member Los Angeles Lipid Association	2010
Past President, California- American Association of Clinical Endocrinologists	2006-8
Chair Task Force & Writing committee Co Chair - AACE 2017 Lipid Guideline	2017
Chair, AACE 2015- Diabetes Mellitus Comprehensive Care Guideline	2015
Chair, AACE/ACE Scientific & Clinical Review: Association of SGLT2i & DKA	2015
Pillar Chair, member of writing committee: AACE Consensus meeting on CGM	2016
Pillar Co-Chair & writing committee: AACE/ACE Consensus Conference on Glucose monitoring.	2014
Member- AACE Consensus Panel on Insulin Pump Management	2014
Member- AACE Consensus Panel on Continuous Glucose Monitors & Glucose Meter	2010
Chair, AACE Consensus on Diabetes, Obesity and Cancer, New York	2012-13
Chair, Workshop & Writing Committee AACE Consensus statement on the Clinical Approach to the detection of Lipodystrophy	2012 -13
Pillar Co-Chair & writing committee: AACE/ACE Consensus Conference on Obesity: Building an Evidence Base for Comprehensive Action	2013
Past Chair & Founder, Diabetes Education programs for Primary Care Physicians and Allied health – CalAACE & National AACE	2004-2016

Member, American Association of Clinical Endocrinologists task force on Guideline For Management of Dyslipidemia and Prevention of Atherosclerosis.	2012
Advisor & Founder AACE Primary Care Physicians, Education Initiative Committee	2010-13
President, American Association of Clinical Endocrinologists	2011-12
President, AACECORP Board of Directors	2011-12
Chancellor, American College of Endocrinology	2012-13
Member, Lipids Resource Center	2018
Member AACE Lipid & CV Health Disease network	2018
Member AACE Diabetes Disease network	2018
Member, AACE, Obesity Disease network	2018
Member, ASPC External Relations Committee	2018
Member, Advocacy Committee, National Lipid Association	2015-
Member & Advisor, AACE Annual Meeting Clinical Congress program committee	2008-19
Endocrine University® Program Committee	2014
Member, Pacific Lipid Association Board of Directors	2009-14
Chair, American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan	2011
Member, Diabetes Committee- Providence Tarzana Medical Center, Tarzana, CA	2008-

### **Journals Editorial Boards**

Editor, The Lipid Forum Online News of the International Lipid Forum	2017-
Associate Editor, “Journal of Diabetes” an international peer reviewed journal, Based in China, devoted to diabetes research, therapeutics, and education	2007-
Member Editorial Panel “European Medical Journal – Diabetes”	2012-
Member, Editorial advisory panel “Treatment Strategies – Diabetes” Cambridge Research center, United Kingdom	2010-
Member, Editorial Advisory Board “Clinical Endocrinology News”	2005-
Member, Editorial Board- “Endocrine Today”	2015-

Guest Editor- “Diabetes and Vascular Disease Research” Journal A Special issue Honoring Gerald Reaven”	2019
Guest Editor- “Journal of Diabetes” The 2 <sup>nd</sup> Heart In Diabetes	2019
Guest Editor- Journal of Clinical Hypertension: Diabetes & Hypertension: Comprehensive Report On Management And The Prevention Of Cardiovascular & Renal Complications	2011
Guest Editor- Postgraduate Medicine Journal: “The Use Of The Bile Acid Sequestrant Colesevelam In Patients With Type 2 Diabetes: For Glucose And Lipid Control”	2009
Guest Editor- Journal of Metabolic Syndrome and Related Disorders: “The 2 <sup>nd</sup> World Congress on the Insulin Resistance Syndrome”	2005

### **Honors and Awards**

Fellow, American Heart Association	2023
Visionary Leader in Medical Education and Cardi-Renal Metabolic Science	2022
Fellow, American Society of Preventive Cardiology	2018
America's best physicians	2018
Master, American College of Endocrinology	2017
Albert Nelson Marquis Lifetime Achievement Award (Marquis Who is Who)	2017
“The Leading Physicians of the world”	2015-
Diabetes Philippines- “Dr. Ricardo E. Fernando Endowed Lectureship Award”	2012
Best Doctors in America	2011-
Medical Science Award of Excellence- American Public Medical Health Group	2011
Fellow, National Lipid Association	2010
Distinguished Leader in Insulin Resistance- International Committee for Insulin Resistance	2008
Super Doctor- “Southern California Super Doctors” Los Angeles Magazine	2008-
Education Recognition Award – World Congress, Insulin Resistance Syndrome	2006
“America’s Top Physicians” – (Consumers Research Council of America)	2006-
Fellow, American College of Endocrinology	2000
Who’s Who in America	2000-

Who's Who in the World	2000-
Who's Who in Medicine and Healthcare	1999-
Fellow, American College of Physicians	1999
Physician Recognition Award with Commendation – American Medical Association	1998
Physician Recognition Award – California Medical Association	1995, 1998
Physician Recognition Award – American Medical Association	1988, 1995
Summa cum Laude – University of the Pacific, Stockton, California	1975
PHI KAPPA PHI – National Academic Honor Society	1975
Highest Honors – San Joaquin Delta College, Stockton, California	1973
ALPHA GAMMA SIGMA – California Academic Honor Society	1973
The Helen E. Danner – Academic Honor Award	1973

## **Medical Societies**

American Heart Association, American Association for Preventive Cardiology, The Endocrine Society, American Diabetes Association, American Association of Clinical Endocrinologists, National Lipid Association, American Thyroid Association, American Medical Association, California medical Association, LA County Medical Assoc.

## **Book**

### **Clinical Management of Cardiovascular Risk in Diabetes and Obesity**

Authors: **Yehuda Handelsman, MD, Robert S. Rosenson.**

Publisher: Professional Communications, Inc.

*First Edition* Copyright 2016; printed in the USA ISBN: 978-1-932610-96-3

## **Book Chapters**

**Epidemiology and its Implications.** Authors: **Zachary B., Yehuda H.** Diabetes in: Lipoproteins In: *Diabetes Mellitus, 2nd ed Jenkins A.J,* 2022 Editor: **Toth P.P (Eds)** Cham: Humana Press. (Contemporary Diabetes)

### **Cardiometabolism: Reducing Risks to Optimize Cardiovascular Disease Outcomes.**

Authors: **Wong N, Handelsman Y.** In: *ASPC Manual of Preventive Cardiology 2021*

Editors **Wong N** et al. Springer ISBN 978-3-030-56278-6

### **Diabetes Mellitus: Recent Developments and Clinical Implications.**

Authors: **Handelsman RG, Handelsman Y.** In: *Manual of Endocrinology and Metabolism, 5th Edition 2018* Editor: **Lavin N Lippincott Manual Series** Wolters Kluwer Health: ISBN 13: 9781496322647

## **Publications**

**Morales J, Handelsman Y** Cardiovascular Outcomes in Patients With Diabetes and Kidney Disease: JACC Review Topic of the Week *J Am Coll Cardiol*. 2023 Jul 11;82(2):161-170. doi: 0.1016/j.jacc.2023.04.052 PMID: 37407115

**Handelsman Y, Butler J, Bakris GL, DeFronzo RA, Fonarow GC, Green JB, Grunberger G, Januzzi JL Jr, Klein S, Kushner PR, McGuire DK, Michos ED, Morales J, Pratley RE, Weir MR, Wright E, Fonseca VA.** Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseases. *J Diabetes Complications*. 2023 Jan 3;37(2):108389. doi: 10.1016/j.jdiacomp.2022.108389. Online ahead of print. PMID: 36669322

**Hamid A, Handelsman Y, Butler J.** DCRM Multispecialty Recommendations in Patients With Heart Failure. *J Card Fail*. 2022 Aug 13:S1071-9164(22)00674-1. doi: 10.1016/j.cardfail.2022.07.053. Online ahead of print. PMID: 35973620

**Miller M, Tokgozoglu L, Parhofer KG, Handelsman Y, Leiter LA, Landmesser U, Brinton EA, Catapano AL.** Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements. *Expert Rev Cardiovasc Ther*. 2022 Jul 28:1-17. doi: 10.1080/14779072.2022.2103541. Online ahead of print. PMID: 35876118

**Handelsman Y, Bunch TJ, Rodbard HW, Steinberg BA, Thind M, Bigot G, Konigsberg L, Wieloch M, Kowey PR** Impact of dronedarone on patients with atrial fibrillation and diabetes: A sub-analysis of the ATHENA and EURIDIS/ADONIS studies. *J Diabetes Complications*. 2022 Jun 8:108227. doi: 10.1016/j.jdiacomp.2022.108227. Online ahead of print. PMID: 35717354

**Handelsman Y, Anderson JE, Bakris GL, Ballantyne CM, Beckman JA, Bhatt DL, Bloomgarden ZT, Bozkurt B, Budoff MJ, Butler J, Dagogo-Jack S, de Boer IH, DeFronzo RA, Eckel RH, Einhorn D, Fonseca VA, Green JB, Grunberger G, Guerin C, Inzucchi SE, Jellinger PS, Kosiborod MN, Kushner P, Lapor N, Mende CW, Michos ED, Plutzky J, Taub PR, Umpierrez GE, Vaduganathan M, Weir MR.** DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. *J Diabetes Complications*. 2022 Feb;36(2):108101. doi: 10.1016/j.jdiacomp.2021.108101. Epub 2021 Dec 7. PMID: 34922811

**Grunberger G, Sherr J, Allende M, Blevins T, Bode B, Handelsman Y, Hellman R, Lajara R, Roberts VL, Rodbard D, Stec C, Unger J.** American Association Of Clinical Endocrinology Clinical Practice Guideline: The Use Of Advanced Technology In The Management Of Persons With Diabetes Mellitus. *Endocr Pract*. 2021 Jun;27(6):505-537. doi:10.1016/j.eprac.2021.04.008. PMID: 34116789

**Handelsman Y, Jellinger PS, Guerin CK, Bloomgarden ZT, Brinton EA, Budoff MJ, Davidson MH, Einhorn D, Fazio S, Fonseca VA, Garber AJ, Grunberger G, Krauss RM, Mechanick JI, Rosenblit PD, Smith DA, Wyne KL** Consensus Statement By The American Association Of Clinical Endocrinologists And American College Of Endocrinology On The Management Of Dyslipidemia And Prevention Of Cardiovascular Disease Algorithm –2020 Executive Summary *Endocr Pract*. 2020 Oct;26(10):1196-1224. doi: 10.4158/CS-2020-0490. PMID: 33471721

**Duprez DA, Handelsman Y, Koren M.** Cardiovascular Outcomes and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Current Data and Future Prospects. *Vasc Health Risk Manag*. 2020 Oct 7;16:403-418. doi: 10.2147/VHRM.S261719. eCollection 2020. PMID: 33116551

**Khan MS, Fonarow GC, McGuire DK, Hernandez AF, Vaduganathan M, Rosenstock J, Handelsman Y, Verma S, Anker SD, McMurray JJV, Kosiborod MN, Butler J.** Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization. *Circulation*. 2020 Sep 22;142(12):1205-1218. doi: 10.1161/CIRCULATIONAHA.120.045888. Epub 2020 Sep 21. PMID: 32955939

**Handelsman Y, Bloomgarden Z.** Paradigm Shift in the management of DM & CVD- Preventing The Next CV Event *J Diabetes*. 2020 Jun 23. doi: 10.1111/1753-0407.13079.

**Bloomgarden Z., Handelsman Y** Management and prevention of cardiovascular disease for type 2 diabetes: Integrating the diabetes management recommendations of AACE, ADA, EASD, AHA, ACC, and ESC *Am J Prev Cardiol* . 2020 May 1;1:100007. doi: 10.1016/j.ajpc.2020.100007.

**Garber AJ, Handelsman Y, Abrahamson MJ, Barzilay JI, Blonde L, Bush, MA, DeFronzo RA, Einhorn D, Garber JR, Garvey WT, Grunberger G, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE.** Consensus Statement By The American Association Of Clinical Endocrinologists And American College Of Endocrinology On The Comprehensive Type 2 Diabetes Management Algorithm - 2020 Executive Summary. *Endocr Pract*. 26 (1), 107-139. PMID: 32022600 DOI:10.4158/CS-2019-0472

**Butler J, Handelsman Y, Bakris G, Verma S,** Use of sodium–glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure. *European Journal of Heart Failure* 2020 Jan; DOI:10.1002/ejhf.1708 [Epub ahead of print]

**Handelsman Y, Muskiet MHA, Meneilly GS.** Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine. *Adv Ther*. 2019 Dec;36(12):3321-3339. doi:10.1007/s12325-019-01126-x. Epub 2019 Oct 23. Review. PubMed PMID: 31646466; PubMed Central PMCID: PMC6860469.

**Bloomgarden Z, Handelsman Y.** Sodium-glucose cotransporter 2 inhibitors for macroalbuminuria: A new indication. *J Diabetes*. 2019 Nov 13. doi: 10.1111/1753-0407.13005. [Epub PMID: 31722441]

**Handelsman Y.** Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes. *Adv Ther*. 2019 Aug 23. doi: 10.1007/s12325-019-01054-w. Epub 2019 Aug 23. Review. PubMed PMID: 31444707; PubMed Central PMCID: PMC6822830

**Bhatt DL, Steg PG, Mehta SR, Leiter LA, Simon T, Fox K, Held C, Andersson M, Himmelmann A, Ridderstråle W, Chen J, Song Y, Diaz R, Goto S, James SK, Ray KK, Parkhomenko AN, Kosiborod MN, McGuire DK, Harrington RA; THEMIS Steering Committee and Investigators.** Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. *Lancet*. 2019 Aug 30. pii: S0140-6736(19)31887-2. doi: 10.1016/S0140-6736(19)31887-2. Epub 2019 Sep 1. PubMed PMID: 31484629

**Steg PG, Bhatt DL, Simon T, Fox K, Mehta SR, Harrington RA, Held C, Andersson M, Himmelmann A, Ridderstråle W, Leonsson-Zachrisson M, Liu Y, Opolski G, Zateyshchikov D, Ge J, Nicolau JC, Corbalán R, Cornel JH, Widimský P, Leiter LA; THEMIS Steering Committee and Investigators.** Ticagrelor in Patients with Stable Coronary Disease and Diabetes. *N Engl J Med*. 2019 Oct 3;381(14):1309-1320. doi:10.1056/NEJMoa1908077. Epub 2019 Sep 1. PubMed PMID: 31475798

**Handelsman Y.** Misconceptions about diabetes management in cardiology. [published online August 6, 2019]. *Cardiology Consultant*



**Handelsman Y.** Comprehensive care in patients with CVD and diabetes [published online July 22, 2019]. *Cardiology Consultant*

**Tomaszewski KJ, Allen A, MocarSKI M, Schiffman A, Kruger D, Handelsman Y, Heile M, Brod M** Divergence in perceptions of diabetes control among patients with type 2 diabetes mellitus treated with basal insulin and health care professionals: results from the US Perceptions of Control (POC-US) study; *Patient Preference and Adherence*; 2019 May 10;13:761-773. doi: 10.2147/PPA.S194598. eCollection 2019. PubMed PMID: 31190758; PubMed Central PMCID: PMC6520481

**Handelsman Y, Bloomgarden Z.** Introduction 2<sup>nd</sup> HiD . *J Diabetes*. 2019 May 7. doi:10.1111/1753-0407.12925. [Epub ahead of print] PubMed PMID: 31066171.

**Handelsman Y.** Gerald Reaven: A man for our times. *Diab Vasc Dis Res*. 2019 Mar;16(2):113-115. doi: 10.1177/1479164119827769. PubMed PMID: 31014094

**Rosenson RS, Daviglus ML, Handelsman Y, Pozzilli P, Bays H, Monsalvo ML, Elliott-Davey M, Somaratne R, Reaven P.** Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomized controlled BANTING study. *Diabetologia*. 2019 Apr 5. doi: 10.1007/s00125-019-4856-7. [Epub ahead of print] PubMed PMID: 30953107.

**Handelsman Y, Wyne K, Cannon A, Shannon M, Schneider D.** Corrections. *J Manag Care Spec Pharm*. 2018 Nov;24(11):1196a. doi: 10.18553/jmcp.2018.24.11.1196a. PubMed PMID: 30806138.

**Mechanick JI, Garber AJ, Grunberger G, Handelsman Y, Garvey WT.** Dysglycemia-Based Chronic Disease: An American Association Of Clinical Endocrinologists Position Statement. *Endocr Pract*. 2018 Nov;24(11):995-1011. doi:10.4158/PS-2018-0139. PubMed PMID: 30763128.

**Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Einhorn D, Fonseca VA, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE.** Consensus Statement By The American Association Of Clinical Endocrinologists And American College Of Endocrinology On The Comprehensive Type 2 Diabetes Management Algorithm - 2019 Executive Summary. *Endocr Pract*. 2019 Jan;25(1):69-100. doi: 10.4158/CS-2018-0535. Erratum in: *Endocr Pract*. 2019 Feb;25(2):204. PubMed PMID: 30742570.

**Li S, Peng Y, Wang X, Qian Y, Xiang P, Wade SW, Guo H, Lopez JAG, Herzog CA, Handelsman Y.** Cardiovascular events and death after myocardial infarction or ischemic stroke in an older Medicare population. *Clin Cardiol*. 2019 Jan 29. doi: 10.1002/clc.23160. [Epub ahead of print] PubMed PMID: 30697776.

**Handelsman Y, Mathieu C, Del Prato S, Johnsson E, Kurlyandskaya R, Iqbal N, Garcia-Sanchez R, Rosenstock J.** Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes. *Diabetes ObesMetab*. 2018 Nov 30. doi: 10.1111/dom.13594. [Epub ahead of print] PubMed PMID:30499237

**Bloomgarden Z, Einhorn D, Handelsman Y, Grunberger G.** Fournier's gangrene and sodium-glucose cotransporter-2 inhibitors: Is there a causal association? *J Diabetes*. 2019 Jan 2. doi: 10.1111/1753-0407.12897. [Epub ahead of print] PubMed PMID: 30600643.

**Handelsman Y, Chovanes C, Dex T, Giorgino F, Skolnik N, Souhami E, Stager W, Niemoeller E, Frias JP.** Efficacy and safety of insulin glargine/lixisenatideb(iGlarLixi) fixed-ratio combination in older adults with type 2 diabetes. *J Diabetes Complications*. 2018 Nov 30. pii: S1056-8727(18)30601-9. doi:10.1016/j.jdiacomp.2018.11.009. [Epub ahead of print] PubMed PMID: 30600136.

**Bloomgarden Z, Handelsman Y.** Notes from the world congress on insulin resistance, diabetes, and cardiovascular disease. *J Diabetes*. 2018 Dec 18. doi: 10.1111/1753-0407.12888. [Epub ahead of print] PubMed PMID: 30561080.

**Mechanick J, Garber A, Grunberger G, Handelsman Y, Garvey W,** Dysglycemia-Based Chronic Disease: An American Association Of Clinical Endocrinologists Position Statement *Endocr Pract*. 2018 Nov DOI: 10.4158/PS-2018-0139 [Epub ahead of print]

**Lingvay I, Handelsman Y, Linjawi S, Vilsbøll T, Halladin N, Ranc K, Liebl A.** Efficacy And Safety Of Ideglira In Older Patients With Type 2 Diabetes. *Endocr Pract*. 2018 Nov 1. doi: 10.4158/EP-2018-0284. [Epub ahead of print] PubMed PMID: 30383495.

**Billings LK, Handelsman Y, Heile M, Schneider D, Wyne K.** Health-Related Quality of Life Assessments with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus. *J Manag Care Spec Pharm*. 2018 Sep;24(9-a Suppl):S30-S41. doi: 10.18553/jmcp.2018.24.9-a.s30. PubMed PMID: 30156447.

**Heile M, Wyne K, Billings LK, Cannon A, Handelsman Y, Shannon M.** Cardiovascular Outcomes with Once-Weekly GLP-1 RAs: Clinical and Economic Implications. *J Manag Care Spec Pharm*. 2018 Sep;24(9-a Suppl):S42-S52. doi: 10.18553/jmcp.2018.24.9-a.s42. PubMed PMID: 30156446.

**Handelsman Y, Wyne K, Cannon A, Shannon M, Schneider D.** Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists. *J Manag Care Spec Pharm*. 2018 Sep;24(9-a Suppl):S14-S29. doi: 10.18553/jmcp.2018.24.9-a.s14. PubMed PMID: 30156445.

**Cannon A, Handelsman Y, Heile M, Shannon M.** Burden of Illness in Type 2 Diabetes Mellitus. *J Manag Care Spec Pharm*. 2018 Sep;24(9-a Suppl):S5-S13. doi: 10.18553/jmcp.2018.24.9-a.s5. PubMed PMID: 30156443.

**Rosenstock J, Handelsman Y, Vidal J, Ampudia Blasco FJ, Giorgino F, Liu M, Perfetti R, Meier JJ.** Propensity-score-matched comparative analyses ofsimultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes. *Diabetes Obes Metab*. 2018 Dec;20(12):2821-2829. doi: 10.1111/dom.13462. Epub 2018 Aug 13. PubMed PMID: 29974618.

**Bloomgarden Z, Handelsman Y.** World congress on insulin resistance, diabetes and cardiovascular disease. *J Diabetes*. 2018 Oct;10(10):776-777. doi: 10.1111/1753-0407.12787. Epub 2018 Jul 4. PubMed PMID: 29971929.

**Handelsman Y, Lepor NE.** PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review. *J Am Heart Assoc*. 2018 Jun 22;7(13). pii: e008953. doi: 10.1161/JAHA.118.008953. Review. PubMed PMID: 29934421

**Bloomgarden Z, Einhorn D, Handelsman Y, Misra A, Zonszein J, Grunberger G, Jellinger PS, Garber AJ.** ACP Diabetes Guidelines Turn Back the Clock, Conflating Good HbA1c with Hypoglycemia. *J Diabetes*. 2018 Apr 14. doi: 10.1111/1753-0407.12668. PubMed PMID: 29655268.

**Bloomgarden Z, Handelsman Y.** Transition from hospital to outpatient diabetes care. *J Diabetes*. 2018 Apr 14. doi: 10.1111/1753-0407.12664. [Epub ahead of print] PubMed PMID: 29655199.

**Grunberger G, Handelsman Y, Bloomgarden ZT, Fonseca VA, Garber AJ, Haas RA, Roberts VL, Umpierrez GE.** American Association Of Clinical Endocrinologists And American College Of Endocrinology 2018 Position Statement On Integration Of Insulin Pumps And Continuous Glucose Monitoring In Patients With Diabetes Mellitus. *Endocr Pract*. 2018 Mar;24(3):302-308. doi: 10.4158/PS-2017-0155. PubMed PMID: 29547046

**Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Einhorn D, Fonseca VA, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE.** Consensus Statement By The American Association Ofclinical Endocrinologists And American College Of Endocrinology On The Comprehensive Type 2 Diabetes Management Algorithm - 2018 Executive Summary. *Endocr Pract*. 2018 Jan;24(1):91-120. doi: 10.4158/CS-2017-0153. Epub 2018 Jan 17. PubMed PMID: 29368965.

**Vinik AI, Camacho PM, Davidson JA, Handelsman Y, Lando HM, Leddy AL, Reddy SK, Cook R, Spallone V, Tesfaye S, Ziegler D;.** American Association Of Clinical Endocrinologists and American College Of Endocrinology Position Statement On Testing For Autonomic & Somatic Nerve Dysfunction *Endocr Pract*. 2017 Dec;23(12):1472-1478. doi: 10.4158/EP-2017-0053. PubMed PMID: 29320641.

**Fonseca VA, Bloomgarden ZT, Dagogo-Jack S, Grunberger G, Einhorn D, Garber AJ, Handelsman Y, Hirsch IB, Umpierrez GE.** Aace/Ace Position Statement On The Use Of Follow-On Biologics And Biosimilars For Endocrine Diseases. *Endocr Pract*. 2017 Nov;23(11):1345-1349. doi: 10.4158/EP-2017-0052. PubMed PMID: 29190135.

**Bloomgarden Z, Handelsman Y.** How does CKD affect HbA1c? *J Diabetes*. 2017 Nov 10. doi: 10.1111/1753-0407.12624. [Epub ahead of print] PubMed PMID: 29124865.

**Bloomgarden ZT, Einhorn D, Handelsman Y.** Response to Comment on Bloomgarden et al. Is HbA(1c) <7% a Marker of Poor Performance in Individuals >65 Years Old? *Diabetes Care* 2017; 40:526-528. *Diabetes Care*. 2017 Oct;40(10):e154. doi:10.2337/dci17-0027. PubMed PMID: 28931711.

**Sabatine MS, Leiter LA, Wiviott SD, Giugliano RP, Deedwania P, De Ferrari GM, Murphy SA, Kuder JF, Gouni-Berthold I, Lewis BS, Handelsman Y, Pineda AL, Honarpour N, Keech AC, Sever PS, Pedersen TR.** Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. *Lancet Diabetes Endocrinol*. 2017 Sep 14. pii: S2213-8587(17)30313-3. doi: 10.1016/S2213-8587(17)30313-3.[Epub ahead of print] PubMed PMID: 28927706.

**Dandona P, Mathieu C, Phillip M, Hansen L, Griffen SC, Tschöpe D, Thorén F, Xu J, Langkilde AM; Handelsman Y- DEPICT-1 Investigators.** Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. *Lancet Diabetes Endocrinol.* 2017 Sep 13. pii: S2213-8587(17)30308-X. doi:10.1016/S2213-8587(17)30308-X. PubMed PMID: 28919061.

**Bloomgarden ZT, Kosiborod MN, Handelsman Y.** Concomitant Diabetes and Atrial Fibrillation: No Sugarcoating the Bittersweet Reality. *J Am Coll Cardiol.* 2017 Sep 12;70(11):1336-1338. doi: 10.1016/j.jacc.2017.07.773. PubMed PMID: 28882230.

**Wysham C, Bhargava A, Chaykin L, de la Rosa R, Handelsman Y, Troelsen LN, Kvist K, Norwood P.** Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial. *JAMA.* 2017 Jul 4;318(1):45-56. doi: 10.1001/jama.2017.7117. PubMed PMID: 28672317.

**Brown WV, Handelsman Y, Martin SS, Morris PB.** JCL roundtable: Future of the lipid laboratory: Using the laboratory to manage the patient (part 2). *J Clin Lipidol.* 2017 May 25. pii: S1933-2874(17)30328-8 doi: 10.1016/j.jacl.2017.05.002. Review. PubMed PMID: 28642100.

**Handelsman Y, Lauring B, Gantz I, Iredale C, O'Neill EA, Wei Z, Suryawanshi S, Kaufman KD, Engel SS, Lai E.** A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy. *Curr Med Res Opin.* 2017 May 26:1-19. doi: 10.1080/03007995.2017.1335638. [Epub ahead of print] PubMed PMID: 28548024.

**Brown WV, Handelsman Y, Martin SS, Morris PB.** JCL roundtable: Future of the lipid laboratory: Choosing valuable measures among the lipoproteins (part 1). *J Clin Lipidol.* 2017 May - Jun;11(3):587-595. doi: 10.1016/j.jacl.2017.04.113. Epub 2017 Apr 21. Review. PubMed PMID: 28465133.

**Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, Grunberger G, Guerin CK, Bell DSH, Mechanick JI, Pessah-Pollack R, Wyne K, Smith D, Brinton EA, Fazio S, Davidson M.** American Association Of Clinical Endocrinologists And American College Of Endocrinology Guidelines For Management Of Dyslipidemia And Prevention Of Cardiovascular Disease. *Endocr Pract.* 2017 Apr;23(Suppl 2):1-87. doi: 10.4158/EP171764.APPGL. PubMed PMID: 28437620.

**Bloomgarden ZT, Einhorn D, Handelsman Y.** Is HbA(1c) <7% a Marker of Poor Performance in Individuals >65 Years Old? *Diabetes Care.* 2017 Apr;40(4):526-528. doi: 10.2337/dci16-0043. PubMed PMID: 28325800.

**Leiter LA, Zamorano JL, Bujas-Bobanovic M, Louie MJ, Lecorps G, Cannon CP, Handelsman Y.** Lipid-Lowering Efficacy and Safety of Alirocumab in Patients with or without Diabetes: A Sub-Analysis of ODYSSEY COMBO II. *Diabetes Obes Metab.* 2017 Feb 16. doi: 10.1111/dom.12909. [Epub ahead of print] PubMed PMID: 28206704.

**Rosenblit PD, Handelsman Y.** Targeting Atherogenic Cholesterol Goals for Patients that Meet the Criteria of 'Extreme' ASCVD Risk. *Lipid Spin, Spring 2017;15(1):7-11.*

**Jellinger PS, Handelsman Y, Bell DS, Bloomgarden ZT, Brinton EA, Davidson M, Fazio S, Fonseca VA, Garber AJ, Grunberger G, Guerin CK, Mechanick JJ, Pessah-Pollack R, Rosenblit PD, Smith D, Wyne K.** American Association Of Clinical Endocrinologists And American College Of Endocrinology Guidelines For Management Of Dyslipidemia And Prevention Of Cardiovascular Disease - *Executive Summary. Endocr Pract.* 2017 Feb 3. doi: 10.4158/EP171764.GL. [Epub ahead of print] PubMed PMID: 28156151.

**Bloomgarden ZT, Mende C, Einhorn D, Handelsman Y,** Diabetes treatment over age 65: Is worse control really better? *J Diabetes.* 2017 Jan 30. doi: 10.1111/1753-0407.12535. [Epub ahead of print] PubMed PMID: 28133929.

**Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Einhorn D, Fonseca VA, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JJ, Rosenblit PD, Umpierrez GE.** Consensus Statement By The American Association Of Clinical Endocrinologists And American College Of Endocrinology On The Comprehensive Type 2 Diabetes Management Algorithm - 2017 Executive Summary. *Endocr Pract.* 2017 Jan 17. doi: 10.4158/EP161682.CS. [Epub ahead of print] PubMed PMID: 28095040.

**Skyler JS, Bakris GL, Bonifacio E, Darsow T, Eckel RH, Groop L, Groop PH, Handelsman Y, Insel RA, Mathieu C, McElvaine AT, Palmer JP, Pugliese A, Schatz DA, Sosenko JM, Wilding JP, Ratner RE.** Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. *Diabetes.* 2016 Dec 15. pii: db160806. [Epub ahead of print] PubMed PMID: 27980006.

**Linjawi S, Bode BW, Chaykin LB, Courrèges JP, Handelsman Y, Lehmann LM, Mishra A, Simpson RW.** The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial. *Diabetes Ther.* 2016 Dec 10. [Epub ahead of print] PubMed PMID: 27943107.

**Handelsman Y, Shapiro MD.** Triglycerides, Atherosclerosis, And Cardiovascular Outcome Studies: Focus On Omega-3 Fatty Acids. *Endocr Pract.* 2016 Nov 7. [Epub ahead of print] PubMed PMID: 27819772.

**Sanon VP, Handelsman Y, Pham SV, Chilton R.** Cardiac Manifestations of Congenital Generalized Lipodystrophy. *Clin Diabetes.* 2016 Oct;34(4):181-186. PubMed PMID: 27766009

**Handelsman Y, Fain R, Wang Z, Li X, Fujioka K, Shanahan W.** Lorcaserin treatment allows for decreased number needed to treat for weight and glycemic parameters in week 12 responders with  $\geq 5\%$  weight loss, *Postgraduate Medicine.* doi:10.1080/00325481.2016.1240591

**Handelsman Y, Henry RR, Bloomgarden ZT, Dagogo-Jack S, DeFronzo RA, Einhorn D, Ferrannini E, Fonseca VA, Garber AJ, Grunberger G, LeRoith D, Umpierrez GE, Weir MR** American Association Of Clinical Endocrinologists And American College Of Endocrinology Position Statement On The Association Of SglT-2 Inhibitors And Diabetic Ketoacidosis. *Endocr Pract.* 2016 Jun;22(6):753-62. doi: 10.4158/EP161292.PS. PubMed PMID: 27082665

**Fonseca VA, Grunberger G, Anhalt H, Bailey TS, Blevins T, Garg SK, Handelsman Y, Hirsch IB, Orzeck EA, Roberts VL, Tamborlane W;** Consensus Conference Writing Committee. Continuous Glucose Monitoring: A Consensus Conference Of The American Association Of Clinical Endocrinologists And American College Of Endocrinology. *Endocr Pract.* 2016 Aug;22(8):1008-21. doi: 10.4158/EP161392.CS. PubMed PMID: 27214060.

**Mechanick JI, Harrell RM, Allende-Vigo MZ, Alvayero C, Arita-Melzer O, Aschner P, Camacho PM, Castillo RZ, Cerdas S, Coutinho WF, Davidson JA, Garber JR, Garvey WT, González FJ, Granados DO, Hamdy O, Handelsman Y, Jiménez-Navarrete MF, Lupo MA, Mendoza EJ, Jiménez-Montero JG, Zangeneh F.** Transculturalization Recommendations For Developing Latin American Clinical Practice Algorithms In Endocrinology - Proceedings Of The 2015 Pan-American Workshop By The American Association Of Clinical Endocrinologists And American College Of Endocrinology. *Endocr Pract.* 2016 Apr;22(4):476-501doi:10.4158/EP161229.GL.PubMed MID: 27031655.

**Bailey TS, Grunberger G, Bode BW, Handelsman Y, Hirsch IB, Jovanović L, Roberts VL, Rodbard D, Tamborlane WV, Walsh J.** American Association Of Clinical Endocrinologists And American College Of Endocrinology 2016 Outpatient Glucose Monitoring Consensus Statement. *Endocr Pract.* 2016 Feb;22(2):231-61. doi: 10.4158/EP151124.CS. Epub 2016 Jan 27. PubMed PMID: 26848630

**Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Einhorn D, Fonseca VA, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Henry RR, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE.** Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm - 2016 executive summary. *Endocr Pract* 2016 Jan;22(1):84-113. doi: 10.4158/EP151126.CS. PubMed PMID: 26731084.

**Bloomgarden ZT, Handelsman Y.** SGLT-2 Inhibition Added to GLP-1 Agonist Therapy for Type 2 Diabetes: What is the benefit? *Endocr Pract.* 2015 Oct 20. [Epub ahead of print] PubMed PMID: 26484408

**Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, Davidson MB, Einhorn D, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE.** Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm - 2015 executive summary. *Endocr Pract.* 2015 Dec;21(12):1403-14. doi: 10.4158/EP151063.CS. PubMed PMID: 26642101

**Bloomgarden ZT, Handelsman Y.** Approaches to treatment 2: Comparison of AACE and ADA type 2 diabetes treatment guidelines. *J Diabetes.* 2015 Oct 2. doi: 10.1111/1753-0407.12345. [Epub ahead of print] PubMed PMID: 26431291.

**Sperling LS, Mechanick JI, Neeland IJ, Herrick CJ, Després JP, Ndumele CE, Vijayaraghavan K, Handelsman Y, Puckrein GA, Araneta MR, Blum QK, Collins KK, Cook S, Dhurandhar NV, Dixon DL, Egan BM, Ferdinand DP, Herman LM, Hessen SE, Jacobson TA, Pate RR, Ratner RE, Brinton EA, Forker AD, Ritzenthaler LL, Grundy SM.** The CardioMetabolic Health Alliance: Working Toward a New Care Model for the Metabolic Syndrome. *J Am Coll Cardiol.* 2015 Sep 1;66(9):1050-67. doi: 10.1016/j.jacc.2015.06.1328. Review. PubMed PMID: 26314534.

**Handelsman Y.** Potential Place of SGLT2 Inhibitors In Treatment Paradigms For Type 2 Diabetes Mellitus. *Endocr Pract.* 2015 Jul 1. PubMed PMID: 26132997.

**Handelsman Y, Bloomgarden ZT, Grunberger G, Umpierrez G, Zimmerman RS, Bailey TS, Blonde L, Bray GA, Cohen AJ, Dagogo-Jack S, Davidson JA, Einhorn D, Ganda OP, Garber AJ, Garvey WT, Henry RR, Hirsch IB, Horton ES, Hurley DL, Jellinger PS, Jovanović L, Lebovitz HE, LeRoith D, Levy P, McGill JB, Mechanick JI, Mestman JH, Moghissi ES, Orzeck EA, Pessah-Pollack R, Rosenblit PD, Vinik AI, Wyne K, Zangeneh F.** American Association Of Clinical Endocrinologists and American College of Endocrinology - Clinical Practice Guidelines for Developing A Diabetes Mellitus Comprehensive Care Plan- 2015. *Endocr Pract.* 2015 Apr;21(Suppl 1):1-87. PMID: 26131596.

**Einhorn D, Handelsman Y, Bode BW, Endahl LA, Mersebach H, King AB.** Patients Achieving Good Glycemic Control (Hba1c <7%) Experience A Lower Rate Of Hypoglycemia With Insulin Degludec Than With Insulin Glargine: A Meta-Analysis Of Phase 3a Trials. *Endocr Pract.* 2015 Jun 29. [Epub ahead of print] PubMed PMID: 26121451.

**Grunberger G, Bailey T, Camacho PM, Einhorn D, Garber AJ, Handelsman Y, Harrell RM, Lando HM, Law B Jr, Leffert JD, Orzeck EA;** Glucose Monitoring Consensus Conference Writing Committee. Proceedings from the american association of clinical endocrinologists and american college of endocrinology consensus conference on glucose monitoring. *Endocr Pract.* 2015 May;21(5):522-33. doi:10.4158/EP15653.CS. PubMed PMID: 25962091.

**Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, Davidson MB, Einhorn D, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez G, Davidson MH.** American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Diabetes Management Algorithm 2015. *Endocr Pract.* Vol 21 No. 4 April 2015.

**Handelsman Y, Bloomgarden ZT, Grunberger G, Umpierrez G, Zimmerman RS, Bailey TS, Blonde L, Bray GA, Cohen AJ, Dagogo-Jack S, Davidson JA, Einhorn D, Ganda OP, Garber AJ, Garvey WT, Henry RR, Hirsch IB, Horton ES, Hurley DL, Jellinger PS, Jovanović L, Lebovitz HE, LeRoith D, Levy P, McGill JB, Mechanick JI, Mestman JH, Moghissi ES, Orzeck EA, Pessah-Pollack R, Rosenblit PD, Vinik AI, Wyne K, Zangeneh F.** American Association of Clinical Endocrinologists and American College of Endocrinology - Clinical Practice Guidelines for Developing a Diabetes Mellitus Comprehensive Care Plan - 2015. *Endocr Pract.* 2015 Apr 1;21(0):1-87. doi: 10.4158/EP15672.GL. PubMed PMID: 25869408.

**Garvey WT, Garber AJ, Mechanick JI, Bray GA, Dagogo-Jack S, Einhorn D, Grunberger G, Handelsman Y, Hennekens CH, Hurley DL, McGill J, Palumbo P, Umpierrez G, On Behalf Of The AACE Obesity Scientific Committee.** American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease. *Endocr Pract.* 2014 Sep 1;20(9):977-89. doi: 10.4158/EP14280.PS.

**Garvey WT, Garber AJ, Mechanick JI, Bray GA, Dagogo-Jack S, Einhorn D, Grunberger G, Handelsman Y, Hennekens CH, Hurley DL, McGill J, Palumbo P, Umpierrez G, On Behalf Of The AACE Obesity Scientific Committee.** American Association of Clinical Endocrinologists and American College of Endocrinology consensus conference on obesity: building an evidence base for comprehensive action. *Endocr Pract.* 2014 Sep 1;20(9):956-76. doi: 10.4158/EP14279.CS. PubMed PMID: 25253226.

**Leiter L, Carr M, Stewart M, Leone-Jones A, Scott R, Yang F, Handelsman Y.** Randomized, Phase III Trial Investigating Efficacy and Safety of the Once Weekly GLP-1 Receptor Agonist Albiglutide Versus Sitagliptin in Patients With Type 2 Diabetes Mellitus and Renal Impairment. Published ahead of print Jul 21 2014 *Diabetes Care*. 2014; 10.2337/db13-859-1394

**Grunberger G, Abelseth JM, Bailey TS, Bode BW, Handelsman Y, Hellman R, Jovanovič Lane WS, Raskin P, Tamborlane WV, Rothermel C.** Consensus statement by the American Association of Clinical Endocrinologists/American College of Endocrinology Insulin Pump Management Task Force. *Endocrine Practice*. 1;20(5):463-89. doi: 10.4158/EP14145.PS. PubMed PMID: 24816754. May 2014.

**Rodbard HW, Gough S, Lane W, Korsholm L, Bretler DM, Handelsman Y.** Reduced risk of hypoglycemia with insulin degludec versus insulin glargine in patients with type 2 diabetes requiring high doses of Basal insulin: a meta-analysis of 5 randomized begin trials. *Endocrine Practice*; 1;20(4):285-92. doi:10.4158/EP13287.OR. PubMed PMID: 24246344. April 2014.

**Bloomgarden Z, Handelsman Y.** Lessons from glargine trials: What is the goal fasting glucose with basal insulin? *J Diabetes*. doi: 10.1111/1753-0407.12152. [Epub ahead of print] PubMed PMID: 24656089. March 2014.

**Gregory RS, Handelsman Y, Pezalla EJ, Pikelny D.** Practical perspectives on the management of overweight and obesity. *Am J Manag Care*. 20(3 Suppl):s64-75. PubMed PMID: 24773374. March 2014.

**Rodbard H, Cariou B, Zinman B, Handelsman Y, Wolden M, Rana A, Mathieu C.** Health status and hypoglycemia with insulin degludec versus insulin glargine: a 2-year trial in insulin-naïve patients with type 2 diabetes. *Diabetes Obesity Metabolism*; doi: 10.1111/dom.12271. [Epub ahead of print] PubMed PMID: 24495158. February 2014.

**Mathieu C, Rodbard HW, Cariou B, Handelsman Y, Philis-Tsimikas A, Francisco AM, Rana A, Zinman B.** A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON). *Diabetes Obesity Metab*; doi: 10.1111/dom.12262. PubMed PMID: 24443830. January 2014.

**Rodbard HW, Cariou B, Zinman B, Handelsman Y, Philis-Tsimikas A, Skjøth TV, Rana A, Mathieu C; BEGIN Once Long trial investigators.** Comparison of insulin degludec with insulin glargine in insulin-naïve subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial. *Diabet Med*. 2013 Nov; 30(11):1298-304. doi: 10.1111/dme.12303. Epub 2013 Sep 30. PubMed PMID: 23952326.

**Zinman B, Rodbard HW, Cariou B, Handelsman Y, Wolden ML, Rana A, Mathieu C.** Physical Health Status and Nocturnal Hypoglycemia with Insulin Degludec vs. Insulin Glargine: A 2-year Trial in Insulin-Naïve Patients with Type 2 Diabetes. *Can J Diabetes*. 2013 Oct;37S4:S54. doi: 10.1016/j.jcjd.2013.08.161 PMID: 24095453

**Einhorn D, Handelsman Y, Bode BW, Endahl L, Mersebach H, Ngo P, King AB** Subjects Achieving Good Glycemic Control (HbA1c<7.0%) Experience a Lower Rate of Confirmed and Nocturnal-Confirmed Hypoglycemia with Insulin Degludec than with Insulin Glargine: A Meta-Analysis of Phase 3a Trials. *Can J Diabetes*. 2013 Oct;37S4:S56. doi: 10.1016/j.jcjd.2013.08.165 PMID: 24095456



**American Association of Clinical Endocrinologists/the American College of Endocrinology; Obesity Society, Gonzalez-Campoy JM, St Jeor ST, Castorino K, Ebrahim A, Hurley D, Jovanovic L, Mechanick JI, Petak SM, Yu YH, Harris KA, Kris-Etherton P, Kushner R, Molini-Blandford M, Nguyen QT, Plodkowski R, Sarwer DB, Thomas KT.** Clinical practice guidelines for healthy eating for the prevention and treatment of metabolic and endocrine diseases in adults: cosponsored by the AACE/the ACE and the Obesity Society: executive summary. *Endocr Pract.* 2013 Sep-Oct;19(5):875-87. doi: 10.4158/EP13155.ESGL. PubMed PMID: 24121263.

**Handelsman Y, Leroith D, Bloomgarden ZT, Dagogo-Jack S, Einhorn D, Garber AJ, Grunberger G, Harrell RM, Gagel RF, Lebovitz HE, McGill JB, Hennekens CH.** Diabetes and cancer—an AACE/ACE consensus statement. *Endocr Pract.* 2013 Jul-Aug;19(4):675-93. doi: 10.4158/EP13248.CS. Erratum in: *Endocr Pract.* 2013 Sep-Oct;19(5):899. PubMed PMID: 23978590.

**Bloomgarden ZT, Drexler A, Einhorn D, Grunberger G, Guan Y, Handelsman Y, Hu JC, Li X, Liu J, Wang W, Weng J, Ning G.** The Journal of Diabetes: continuing the dialogue. *J Diabetes.* 2013 Jun;5(2):95-6. doi: 10.1111/1753-0407.12045. PubMed PMID: 23489930.

**Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, Davidson MB, Einhorn D, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez G, Davidson MH.** AACE Comprehensive Diabetes Management Algorithm consensus statement- executive summary. 2013. PMID: 23816937 *Endocr Pract.* 2013 May-Jun;19(3):536-57.

**Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, Davidson MB, Einhorn D, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez G, Davidson MH.** AACE Comprehensive Diabetes Management Algorithm 2013. PMID:23598536 *Endocr Pract.* 2013 Mar-Apr;19(2):327-36.

**Bloomgarden ZT, Drexler A, Einhorn D, Grunberger G, Guan Y, Handelsman Y, Hu JC, Li X, Liu J, Wang W, Weng J, Ning G.** The Journal of Diabetes: Continuing the Dialogue. *J Diabetes.* 2013 Mar 13. doi: 10.1111/1753-0407.12045.

**Bloomgarden Z, Handelsman Y.** Sugar-sweetened beverages: Changing the tide. *J Diabetes.* 2013 March 10. doi: 10.1111/1753-0407.12021.

**Handelsman Y, Oral EA, Bloomgarden ZT, Brown RJ, Chan JL, Einhorn D, Garber AJ, Garg A, Garvey WT, Grunberger G, Henry RR, Lavin N, Tapiador CD, Weyer C.** The clinical approach to the detection of lipodystrophy - an AACE consensus statement. *Endocr Pract.* 2013 Jan-Feb;19(1):107-16.

**Mechanick JI, Garber AJ, Handelsman Y, Garvey WT, McMahon MM, Hurley DL.** Authors' Response to Lorenzo Donini, MD. *Endocr Pract.* 2013 Jan 21:1-4.

**Garber AJ, Blonde L, Bloomgarden ZT, Handelsman Y, Dagogo, Jack S.** The Role of Bromocriptine-QR in the Management of Type 2 Diabetes Expert Panel Recommendations. *Endo Pract.* 2013 Jan 21:1-22.

**Zinman B, Philis-Tsimikas A, Cariou B, Handelsman Y, Rodbard HW, Johansen T, Endahl L, Mathieu C;** On behalf of the NN1250-3579 (BEGIN Once Long) Trial Investigators. Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes: A 1-year, randomized, treat-to-target trial (BEGIN Once Long) *Diabetes Care* 2012 Oct 5 (ahead of print)

**McMahon MM, Hurley DL, Mechanick JI, Handelsman Y.** AACE's position statement on clinical nutrition and health promotion in endocrinology. *Endocr Pract.* 2012 Sep 1;18(5):633-41

**Mechanick JI, Garber AJ, Handelsman Y, Garvey WT.** AACE's position statement on obesity and obesity medicine. *Endocr Pract.* 2012 Sep 1;18(5):642-8.

**Rosenstock J, Hernandez-Triana E, Handelsman Y, Misir S, Jones MR.** Clinical effects of colesevelam in Hispanic subjects with primary hyperlipidemia and prediabetes *Postgrad Med.* 2012 Jul;124(4):14-20

**Rosenstock J, Hernandez-Triana E, Handelsman Y, Misir S, Jones MR, Nagendran S.** Initial combination therapy with metformin plus colesevelam in drug naïve Hispanic patients with type 2 diabetes *Postgrad Med.* 2012 Jul;124(4):7-13

**Jellinger PS, Smith DA, Mehta AE, Ganda O, Handelsman Y, Rodbard HW, Shepherd MD, Seibel JA; AACE Task Force for Management of Dyslipidemia and Prevention of Atherosclerosis.** American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. *Endocr Pract.* 2012 Mar-Apr;18 Suppl 1:1-78. PubMed PMID: 22522068.

**Jellinger PS, Smith DA, Mehta AE, Ganda O, Handelsman Y, Rodbard HW, Shepherd MD, Seibel JA** AACE Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis Executive Summary. *Endocrine Practice* Vol 18 March/April 2012 269-93

**Bloomgarden Z, Handelsman Y.** An interview with the authors of Did AIM-HIGH aim too low. Interview by Jinghong Xu. *J Diabetes.* 2012 Mar;4(1):3. doi: 10.1111/j.1753-0407.2012.00191.x. PubMed PMID: 22360791.

**Bloomgarden Z, Handelsman Y.** Did AIM-HIGH aim too low? *J Diabetes.* 2012 Mar;4(1):1-2. doi: 10.1111/j.1753-0407.2011.00176.x. PubMed PMID: 22141573.

**Moses AC, Handelsman Y, Einhorn D,** Effectiveness of primary care-relevant treatments for obesity in adults, *Ann Intern Med.* 2012 Feb 7;156(3):248-9;

**Handelsman Y, Fonseca V, Rosenstock J.** Is combination therapy an effective way of reaching lipid goals in Type 2 diabetes mellitus? *Expert Rev Clin Pharmacol.* 2012 Jan;5(1):43-54. PubMed PMID: 22142158.

**Bloomgarden Z, Handelsman Y, Einhorn D.** Comprehensive diabetes cardiovascular treatment = Sugar + BP + Lipids. *Journal of Diabetes* 2011 Dec;3(4):257-60

**Bloomgarden Z, Handelsman Y.** Did AIM-HIGH aim too low? *J Diabetes.* 2011 Dec 5. doi: 10.1111/j.1753-0407.2011.00176.x.

**Handelsman Y, Jellinger PS.** Overcoming obstacles in risk factor management in type 2 diabetes mellitus. *Journal of Clinical Hypertension* 2011 August;13(8):613-20 Epub 2011 Jul 14. Review. PubMed PMID:21806772.

**Handelsman Y, Bloomgarden Z.** Diabetes in youth: a dilemma of pathogenesis. *Journal of Diabetes* 2011 June;3(2):91-2.

**Handelsman Y.** Role of bile acid sequestrants in the treatment of type 2 diabetes. *Diabetes Care* 2011 May;34 Suppl 2:S244-50.

**Handelsman Y.** Diabetes and hypertension: a comprehensive report on management and the prevention of cardiovascular and renal complications. *J Clin Hypertens (Greenwich)*. 2011 Apr;13(4):221-3. doi: 10.1111/j.1751-7176.2011.00453.x. PubMed PMID: 21466616.

**Handelsman Y, Mechanick JI, Blonde L, Grunberger G, Bloomgarden ZT, Bray GA, Dagogo-Jack S, Davidson JA, Einhorn D, Ganda O, Garber AJ, Hirsch IB, Horton ES, Ismail-Beigi F, Jellinger PS, Jones KL, Jovanović L, Lebovitz H, Levy P, Moghissi ES, Orzeck EA, Vinik AI, Wyne KL;** American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. *Endocrine Practice* 2011 Mar-Apr;17 Suppl 2.

**Handelsman Y, Mechanick JI, Blonde L, Grunberger G, Bloomgarden ZT, Bray GA, Dagogo-Jack S, Davidson JA, Einhorn D, Ganda O, Garber AJ, Hirsch IB, Horton ES, Ismail-Beigi F, Jellinger PS, Jones KL, Jovanović L, Lebovitz H, Levy P, Moghissi ES, Orzeck EA, Vinik AI, Wyne KL** AACE Task Force for Developing a Diabetes Comprehensive Care Plan; American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan: executive summary. *Endocrine Practice* 2011 Mar-Apr;17(2):287-302.

**Ford ES, Cowie CC, Li C, Handelsman Y, Bloomgarden ZT.** Iron-deficiency anemia, non-iron-deficiency anemia and HbA1c among adults in the US. *Journal of Diabetes* 2011 Mar;3(1):67-73.

**Bloomgarden Z, Handelsman Y.** The Avandia debate: an unhappy conclusion. *Journal of Diabetes* 2010 Dec;2(4):221-2.

**Handelsman Y.** The role of bile acid sequestrants in the management of type 2 diabetes mellitus: summary and future directions. *Metabolic Syndrome & Related Disorders* 2010 Dec;8

**Grunberger G, Bailey TS, Cohen AJ, Flood TM, Handelsman Y, Hellman R, Jovanović L, Moghissi ES, Orzeck EA** AACE Insulin Pump Management Task Force. Statement by the American Association of Clinical Endocrinologists Consensus Panel on insulin pump management. *Endocrine Practice* 2010 Sep-Oct; 16(5):746-62

**Bloomgarden ZT, Ning G, Drexler AJ, Guan YF, Handelsman Y, Li XY, Liu JM** Good news! *Journal of Diabetes* 2010 Sep;2(3):127

**Zhang Y, Ning G, Handelsman Y, Bloomgarden ZT** Gut hormones and the brain. *Journal of Diabetes* 2010 Sep;2(3):138-45

**Ratner RE, Rosenstock J, Boka G, Handelsman Y, DRI6012 Study Investigators.** Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. *Diabetic Medicine* 2010 Sep;27(9):1024-32

**Handelsman Y, Goldberg RB, Garvey WT, Fonseca VA, Rosenstock J, Jones MR, Lai YL, Jin X, Misir S, Nagendran S, Abby SL** Colesevelam hydrochloride to treat hypercholesterolemia and improve glycemia in prediabetes: a randomized, prospective study. *Endocrine Practice* 2010 Jul-Aug;16(4):617-28

**Rosenstock J, Fonseca VA, Garvey WT, Goldberg RB, Handelsman Y, Abby SL, Lai YL, Jin X, Misir S, Nagendran S, Jones MR.** Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetes. *Endocrine Practice* 2010 Jul-Aug;16(4):629-40

**Bloomgarden Z, Drexler A, Handelsman Y.** Insulin treatment of Type 2 diabetes: a clinical perspective. *J Diabetes*. 2010 Jun;2(2):65-6. doi: 10.1111/j.1753-0407.2010.00073.x. Epub 2010 Mar 25. PubMed PMID: 20923487.

**Fonseca VA, Handelsman Y, Staels B.** Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence. *Diabetes Obesity Metabolism* 2010 May;12(5):384-92. Review.

**Staels B, Handelsman Y, Fonseca V.** Bile Acid Sequestrants for Lipid and Glucose Control. *Current Diabetes Reports* March 2010; 10: 70-77

**Rigby SP, Handelsman Y, Lai YL, Abby SL, Tao B, Jones MR.** Effects of colesevelam HCl, rosiglitazone, or sitagliptin on glycemic control and the lipid profile in subjects with type 2 diabetes inadequately controlled on metformin monotherapy. *Endocrine Practice* 2010;16:53–63.

**Bloomgarden, Z., Drexler A, Handelsman, Y** Editorial- Insulin treatment of Type 2 diabetes: a clinical perspective. *Journal of Diabetes*; 2010; 2: 65–66.

**Bloomgarden Z, Handelsman Y.** Cancer mortality and insulin glargine. *J Diabetes*. 2009 Sep;1(3):131-3. doi: 10.1111/j.1753-0407.2009.00038.x. Epub 2009 Jul 2. PubMed PMID: 20923531.

**Handelsman Y.** The role of colesevelam HCl in type 2 diabetes mellitus therapy. *Postgrad Med* 2009 May; 121 (3 suppl 1) 19-24.

**Handelsman Y.** The use of the bile acid sequestrant colesevelam HCl in patients with type 2 diabetes mellitus: for glucose and lipid control- Introduction.-. *Postgrad Med* 2009 May;121(3 Suppl 1): p5-6.

**Handelsman Y, Abby SL, Jin X, Donovan JM, Jones MR.** Colesevelam HCl improves fasting plasma glucose and lipid levels in patients with prediabetes. *Postgrad Med* Nov 2009;121:62–69.

**Rodbard, H., Jellinger, P., Handelsman, Y et al.** Consensus Panel on Type 2 Diabetes Mellitus: Algorithm for Glycemic Control. *Endocrine Practice*, 2009 Sep-Oct 15(6), 540-559. Erratum in: *Endocrine Practice*. 2009 Nov-Dec;15(7):768-70. PubMed PMID: 19858063.

**Handelsman Y.** Metabolic syndrome pathophysiology and clinical presentation. *Toxicologic Pathology*. 2009; 37(1):18-20

**Hsueh, WA, Handelsman, Y,** “Pharmacologic treatment options for prediabetes.-View Point “ *Nature Clinical Practice Endocrinology & Metabolism*. 2008 Jul;4(7):380-1. Epub 2008 Jun 3

**Handelsman Y,** “Treating Diabetes with Incretin Hormones - Clinical Experience” *Pediatric Endocrinology Reviews (PER)* 5: 4 June 2008 898-904

**Garber AJ, Handelsman Y, Einhorn D, et al.** Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the ACE and the AACE. *Endocr Pract*. 2008; 14: 7:933-46

**Jellinger, PS, Davidson, JA, Blonde, L, Einhorn, D, Grunberger, G, Handelsman, Y, et al.** “Road Maps to Achieve Glycemic Control in Type 2 Diabetes Mellitus” *Endocrine Practice*. May/June 2007;vol 13: 1: 260-8

**Rodbard, HW, Blonde, L, Braithwaite, SS, Brett, EM, Cobin, RH, Handelsman, Y, et al.** “Medical Guidelines For Clinical Practice For The Management Of Diabetes Mellitus” *Endocrine Practice*;vol 13:, Suppl. 1 May/June 2007

**Mechanick JI, Handelsman Y, Bloomgarden ZT.** “Hypoglycemia in the intensive care unit” *Current Opinion in Clinical Nutrition and Metabolic Care* 2007,10:193–196

**Lebovitz HE, Austin MM, Blonde L, Davidson JA, Del Prato S, Gavin JR 3rd, Handelsman Y, et al.** ACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: Position statement. *Endocr Pract*. 2006 Jan-Feb;12 Suppl 1:6-12

**Handelsman Y,** Guest Editorial-“The 2<sup>nd</sup> World Congress on the Insulin Resistance Syndrome” *Journal of Metabolic Syndrome and Related Disorders*, 2005; 3: 4: 243–245

**Cobin RH, Futterweit W, Handelsman Y, et al** “AACE position Statement on Metabolic and Cardiovascular Consequences of Polycystic Ovary Syndrome” *Endocrine Practice*. 2005;11:125

**Futterweit W, Nestler JE, Reaven GM, Jellinger PS, Handelsman Y, Redmond GP, Thatcher SS.** AACE Position Statement on Polycystic Ovary Syndrome, *Endocr Pract*. 2005;11(No. 2)

**Handelsman Y,** “Treatment of Insulin Resistance Syndrome”, *Endocrine Practice*. 2003;9 suppl 2; 99-104

**Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y, et al.** ACE Position Statement on the Insulin Resistance Syndrome. *Endocr Pract*. 2003;9(3):240-52.

### **Abstracts/Posters (partial List)**

**Juan P. Frias, Richard J. Auchus, Irina Bancos, Lawrence Blonde, Robert S. Busch, John B. Buse, Ralph A. DeFronzo, Vivian Fonseca, Oksana Hamidi, Yehuda Handelsman, Richard E. Pratley, Julio Rosenstock, Iulia Cristina Tudor, Andreas G. Moraitis, Daniel Einhorn,** Catalyst -A Phase 4 Study of Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes Despite Receiving Standard-of-Care Therapies, Assessing Prevalence and Treatment with Mifepristone *The Endocrine Society* Chicago 2023

**Handelsman Y, Steinberg B, Rodbard H, Bunch J, Thind M, Bigot G, Konigsberg L, Wieloch M, Bhattacharyya N, Kowey P.** impact of dronedarone on patients with atrial fibrillation and diabetes - A sub-analysis of the ATHENA and EURIDIS/ADONIS trials. *European Society of Cardiology* Congress 2021

**Yehuda Handelsman, MD, Andrea Giaccari, MD, Sangeeta Sawhney, MD, Phillip Banks, M, Michael J. Davies, PhD3, Pablo Lapuerta, MD** Efficacy and Safety of Sotagliflozin by Baseline Renal Function in Adults With Type 1 Diabetes *American Diabetes Association Annual Meeting*, Virtual 2020

**Brod M, Tomaszewski KJ, Allen A, Kruger D, Heile M, Mocarski M, Schiffman A, Handelsman Y** Divergence in Perceptions of Diabetes Control Among Patients with T2DM and Healthcare Professionals (HCPs) *American Diabetes Association Annual Meeting*, Orlando 2018

**Brod M, Tomaszewski KJ, Allen A, Kruger D, Heile M, Mocarski M, Schiffman A, Handelsman Y** Differences in Patient Perspectives of Type 2 Diabetes Management and Care by Current A1C **American Diabetes Association Annual Meeting**, Orlando 2018

**Yehuda Handelsman, Chantal Mathieu, Stefano Del Prato, Eva Johnsson, Raisa Kurlyandskaya, Nayyar Iqbal, Ricardo Garcia-Sanchez and Julio Rosenstock** Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin as add-on to metformin in uncontrolled type 2 diabetes **53rd Annual Meeting of the European Association for the Study of Diabetes** Lisbon 2017

**Stefano Del Prato, Yehuda Handelsman, Chantal Mathieu, Eva Johnsson, Raisa Kurlyandskaya, Nayyar Iqbal, Ricardo Garcia-Sanchez, Julio Rosenstock** Dapagliflozin + saxagliptin add-on to metformin (triple therapy) versus sitagliptin add-on to metformin (dual therapy) in subgroups of patients with uncontrolled type 2 diabetes. **53rd Annual Meeting of the European Association for the Study of Diabetes** Lisbon 2017

**Suying Li, Yi Peng, Xinyue Wang, Yi Qian, Pin Xiang, Sally Wade, Haifeng Guo, J. Antonio Lopez, Yehuda Handelsman, Charles A. Herzog** Cardiovascular Event Rates After Myocardial Infarction or Ischemic Stroke in Older Medicare Patients **American Heart Association Scientific Sessions**. Anaheim 2017

**Yehuda Handelsman, Christina Chovanes, Terry Dex, Francesco Giorgino, Neil Skolnik, Elisabeth Souhami, William Stager, Juan-Pablo Frias** Efficacy And Safety Of Insulin Glargine/Lixisenatide Fixed-Ratio Combination In Elderly Patients With Type 2 Diabetes **AANP** 2017

**Carol Wysham, Anuj Bhargava, Louis Chaykin, Raymond de la Rosa, Yehuda Handelsman, Lone N Troelsen, Kajsa Kvist, Paul Norwood** Consistent hypoglycemia benefit for Insulin Degludec (IDeg) vs Insulin Glargine (IGlar) in Patients with T2D at high risk of severe hypoglycemia: A Randomized, Double Blind, Crossover Trial **American Diabetes Association Annual Meeting**, New Orleans, 2016

**Y. Handelsman, C. Chovanes, T. Dex, F. Giorgino, N. Skolnik, E. Souhami, W. Stager, J.P. Frias**; Efficacy and safety of insulin glargine/lixisenatide fixed ratio combination in elderly patients with type 2 diabetes **52<sup>nd</sup> Annual Meeting of the European Association for the Study of Diabetes** Munich 2016

**Yehuda Handelsman, Randi Fain, Zhixiao Wang, Xuan Li, Ken Fujioka & William Shanahan** Lorcaserin treatment allows for decreased number needed to treat for weight and glycemic parameters in week 12 responders with  $\geq 5\%$  weight loss **AACE Annual** Orlando 2016

**Naveed Sattar, Paul Valensi, David Preiss, Ricardo Dent, Ian Bridges, Andrea Ruzza, Marcoli Cyrille, Yehuda Handelsman** Long-term efficacy of evolocumab in reducing lipids in EU subjects with and without type 2 diabetes: An analysis from the open-label extension OSLER studies **52<sup>nd</sup> Annual Meeting of the European Association for the Study of Diabetes** Munich 2016

**Linjawi S, Bode B, Cannon A, Chaykin L, Courreges JP, Handelsman Y, Lehmann LM, Mishra A, Simpson R** Efficacy and Safety of IDegLira (Combination of Insulin Degludec + Liraglutide), in Insulin Naïve Patients with T2D uncontrolled on GLP-1 receptor agonist (GLP-1RA) Therapy **American Diabetes Association Annual Meeting**, Boston 2015

**Yehuda Handelsman, Randi Fain, Alan Glicklich, Yuhan Li, William Shanahan, William Soliman** Determination of Number Needed to Treat With Lorcaserin to Achieve HbA1c Reductions of  $\geq 0.5\%$  in Patients With Overweight and Obesity, and With Type 2 Diabetes: A Retrospective Analysis of the BLOOM-DM Study. *The Obesity Week*, November 2014, Boston MA

**Lawrence A. Leiter,, Molly C. Carr,, Murray Stewart,Angela Jones-Leone, Fred Yang, Yehuda Handelsman.** HARMONY 8: Once-weekly Glucagon-Like Peptide 1 Receptor Agonist Albiglutide vs Sitagliptin for Patients With Type 2 Diabetes With Renal Impairment: Week 26 Results. *German Diabetes Society Annual Conference*, May 2014 in Berlin, Germany

**Russell-Jones D, Mathieu C, Rodbard H, Cariou B, Handelsman Y, Philis-Tsimikas A, AOFR, AZRN, Zinman B.** Liraglutide add-on to insulin degludec plus metformin vs addition of a single dose of insulin aspart to the largest meal in patients with type 2 diabetes. *Diabetes UK Annual Meetings*, March 2014, Liverpool UK

**H.W. Rodbard, W. Lane, Y. Handelsman, T.M. Hobbs, L. Korsholm, S.C.L. Gough.** A reduced risk of nocturnal hypoglycaemia in patients with T1D requiring high dose basal insulin: insulin degludec vs. insulin glargine. *International Diabetes Federation Meeting*, December 2013, Melbourne, Australia.

**Yehuda Handelsman, MD; Sarah Odeh, BS; Barbara Troupin, MD.** Use of Phentermine/Topiramate Extended-Release in a Spectrum of Obese/ Overweight Subjects With Dysglycemia. *11 World Congress on Insulin Resistance (WCIRDC)*, November 2013, Los Angeles CA.

**HW Rodbard, W Lane, Y Handelsman, TM Hobbs, L Korsholm, SCL Gough.** A reduced risk of nocturnal hypoglycaemia in patients with T1D requiring high dose basal insulin: insulin degludec vs. insulin glargine. *Annual Meeting of the European Association for the Study of Diabetes (EASD)*, September 2013, Barcelona, Spain.

**HW Rodbard, W Lane, Y Handelsman, TM Hobbs, L Korsholm, SCL Gough.** A reduced risk of nocturnal hypoglycaemia in patients with T1D requiring high dose basal insulin: insulin degludec vs. insulin glargine. *Canadian Diabetes Association Annual Meetings*, October 2013, Montreal, Canada

**Lawrence A. Leiter,, Molly C. Carr,, Murray Stewart,Angela Jones-Leone, Fred Yang, Yehuda Handelsman.** HARMONY 8: Once-weekly Glucagon-Like Peptide 1 Receptor Agonist Albiglutide vs Sitagliptin for Patients With Type 2 Diabetes With Renal Impairment: Week 26 Results. *American Diabetes Association Annual Meeting*, Chicago 2013

**Helena W. Rodbard, Bertrand Cariou, Bernard Zinman, Yehuda Handelsman, Michael L. Wolden, Azhar Rana, Chantal Mathieu.** Physical Health Status and Nocturnal Hypoglycemia with Insulin Degludec vs. Insulin Glargine: A 2-Year Trial in Insulin-Naïve Patients with Type 2 Diabetes. *American Diabetes Association Annual meeting*, Chicago 2013

**Mathieu C, Rodbard HW, Cariou B, Handelsman Y, Philis-Tsimikas A, Francisco AM, Rana A, Zinman B.** Comparison of Addition of Liraglutide to Insulin Degludec Plus Metformin vs Addition of a Single Dose Of Insulin Aspart to Largest Meal in Type 2 Diabetes. *American Diabetes Association Annual meeting*, Chicago 2013

**Bernard Zinman, Athena Philis-Tsimikas,<sup>2</sup>Yehuda Handelsman, Helena W Rodbard, Bertrand**

**Cariou, Thue Johansen, Lars Endahl, Chantal Mathieu.** Effect of insulin degludec on glycaemic control and nocturnal hypoglycaemia compared with insulin glargine: a 1-year trial in insulin-naïve patients with type 2 diabetes. *Annual Meeting of the European Association for the Study of Diabetes (EASD)*, Berlin, Germany, October 2012

**H.W. Rodbard, B. Zinman, B. Cariou, A. Philis-Tsimika, Y. Handelsman, T.V. Skjøth, P.L. Chu, C. Mathieu.** Reduced nocturnal hypoglycaemia with insulin degludec as compared to insulin glargine: results of a 2-year randomised trial in type 2 diabetes. *Annual Meeting of the European Association for the Study of Diabetes (EASD)*, Berlin, Germany, October 2012

**Rodbard H, Gough S, Handelsman Y,** Reduced risk of hypoglycemia with insulin degludec vs insulin glargine in patients with type 2 diabetes requiring high doses of basal insulin: meta-analysis of five randomized trials" *Canadian Diabetes Association Annual*, Vancouver, Canada, October 2012.

**Zinman B, Philis-Tsimikas A, Handelsman Y, Rodbard HW, Cariou B, Endahl L Mathieu C.** The Effect of Insulin Degludec on Glycemic Control and Nocturnal Hypoglycemia Compared with Insulin Glargine: a 1-year Randomized Trial in Insulin-naïve People with Type 2 Diabetes Canadian Diabetes Association Annual Conference, Vancouver, Canada, October 2012

**Dan Einhorn, Yehuda Handelsman, Bruce Bode, Lars Endahl,<sup>4</sup>Henriette Mersebach, Allen King** Subjects achieving good glycemic control (HbA<sub>1C</sub> < 7.0%) experience a lower rate of confirmed and nocturnal confirmed hypoglycemia with insulin degludec than with insulin glargine: a meta-analysis of phase 3a trials. *Annual Meeting of the Endocrine Society ENDO 2012*, Houston, Texas, June 2012

**Rodbard H , Handelsman Y, Cariou B, Johansen T, Christensen T, Mathieu C.** Insulin Degludec Reduces Hypoglycemia and Improves Health Status vs. Insulin Glargine in Insulin-naïve Type 2 Diabetes *American Diabetes Association Annual Meeting*, Philadelphia 2012

**Zinman B, Philis-Tsimikas A, Handelsman Y, Rodbard HW, Cariou B, Endahl L Mathieu C.** The Effect of Insulin Degludec on Glycemic Control and Nocturnal Hypoglycemia Compared with Insulin Glargine: a 1-year Randomized Trial in Insulin-naïve People with Type 2 Diabetes American Diabetes Association Annual meeting, Philadelphia 2012

**Helena Rodbard, MD, Stephen Gough, MD" ; Yehuda Handelsman, MD.** Reduced risk of hypoglycemia with insulin degludec vs insulin glargine in patients with T2D requiring high doses of basal insulin: meta-analysis of five randomized trials" *AACE Annual Meetings*, Philadelphia 2012.

**Harold E. Bays, MD;<sup>1</sup> Ishwarlal Jialal, MD, PhD;<sup>2</sup> Philip Levy, MD;<sup>3</sup> Soamnauth Misir, PharmD;<sup>4</sup> Michael R. Jones, PhD;<sup>4</sup> Kenneth E. Truitt, MD;<sup>5</sup> Yehuda Handelsman, MD<sup>6</sup>** Colesevelam added to background metformin therapy in patients with type 2 diabetes mellitus: a pooled lipid analysis from three clinical studies. *American Association of Clinical Endocrinologists (AACE) Annual Meetings*, San Diego, CA, April 2011

**W. Timothy Garvey, MD; Ronald B. Goldberg, MD; Yehuda Handelsman, MD; Vivian A. Fonseca, MD; Eric Hernandez-Triana, MD; Michael R. Jones, PhD; Stacey L. Abby, PharmD;<sup>6</sup> Xiaoping Jin, PhD; Soamnauth Misir, PharmD; Sukumar Nagendran, MD; Julio Rosenstock, MD.** Colesevelam significantly reduces low-density lipoprotein particle concentration in patients with prediabetes and hypercholesterolemia. *8<sup>th</sup> World Congress on Insulin Resistance Diabetes and Cardiovascular Disease (WCIRDC)*, November 2010, Los Angeles, CA

**Goldberg RB, Garvey WT, Fonseca VA, Handelsman Y, Hernandez-Triana E, Jones MR, Abby**



**SL, Jin X, Misir S, Nagendran S, Rosenstock J.** Colesevelam in Combination with Metformin Significantly Reduces Low-Density Lipoprotein Particle Concentration in Patients with Early Type 2 Diabetes. *American Heart Association (AHA) Scientific Sessions*, Chicago, IL, November 2010

**Garvey WT, Goldberg RB, Handelsman Y, Fonseca VA, Hernandez-Triana E, Jones MR, Abby SL, Jin X, Misir S, Nagendran S, Rosenstock J, MD.** Treatment with Colesevelam Significantly Reduces Low-Density Lipoprotein Particle Concentration in Patients with Prediabetes and Hypercholesterolemia. *American Heart Association (AHA) Scientific Sessions*, Chicago, IL, Nov 2010.

**Goldberg RB; Rosenstock J; Garvey WT; Fonseca VA; Hernandez-Triana E; Handelsman Y; Jones MR; Lai Y-L; Jin X; Misir S; Nagendran S; Abby SL.** The use of Colesevelam for Hispanic patients with hypercholesterolemia and prediabetes. *Annual Meeting of the European Association for the Study of Diabetes (EASD)*, Stockholm, Sweden, September 2010

**Garvey WT; Goldberg RB; Hernandez-Triana E; Handelsman Y; Fonseca VA; Jones MR; Abby SL; Markiewicz M; Jin X; Misir S; Nagendran S; Rosenstock J.** Initial treatment with metformin + colesevelam provides greater glycemic control than metformin alone in Hispanic patients with early type 2 diabetes mellitus. *Annual Meeting of the European Association for the Study of Diabetes (EASD)*, Stockholm, Sweden, September 2010

**Garvey WT; Goldberg RB; Hernandez-Triana E; Handelsman Y; Fonseca VA; Jones MR; Abby SL; Markiewicz M; Jin X; Misir S; Nagendran S; Rosenstock J.** Initial treatment with metformin + colesevelam provides greater glycemic control than metformin alone in Hispanic patients with early type 2 diabetes mellitus. *American College of Clinical Pharmacy Annual Meeting* October, 2010, Austin, TX

**Rosenstock J, Fonseca VA, Garvey WT, Goldberg RB, Handelsman Y, Abby SL, Lai Y-L, Jin X, Misir S; Nagendran S, Jones MR.** Initial combination therapy with metformin + colesevelam safely achieves glycemic and lipid goals with less diarrhea in early type 2 diabetes mellitus. *American Diabetes Association 70<sup>th</sup> Scientific Sessions (ADA)*, Orlando, FL, June, 2010.

**Abby SL; Garvey WT, Handelsman Y, Fonseca VA, Goldberg RB, Rosenstock J, Jones MR, Markiewicz M, Jin X, Misir S, Nagendran S.** The safety and tolerability of metformin + colesevelam in drug-naïve patients with early type 2 diabetes mellitus. *American Diabetes Association 70<sup>th</sup> Scientific Sessions (ADA)*, Orlando, FL, June, 2010.

**Handelsman Y.** The Role of Bile Acid Sequestrants in Treatment of Type 2 Diabetes Mellitus. *World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy)*, Prague, Czech Republic, May 2010.

**Handelsman Y, Goldberg RB, Garvey WT, Fonseca VA, Rosenstock J, Jones MR, Lai Y-L, Jin X, Misir S, Nagendran S, Abby SL.** Colesevelam HCl to Treat Hypercholesterolemia & Improve Glycemia in Prediabetes: A Randomized, Prospective Study. *AACE Annual Meetings*, Boston, MA, April 2010

**Handelsman Y, Goldberg RB, Garvey WT, Fonseca VA, Rosenstock J, Jones MR, Lai Y-L, Jin X, Misir S, Nagendran S, Abby SL.** Colesevelam HCl to Treat Hypercholesterolemia and Improve Glycemia in Prediabetes: A Randomized, Prospective Study. *National Lipid Association 2010 Scientific Sessions (NLA—abstract and poster AACE encore)* May 13 - 16, 2010, Chicago, IL

**Gonzalez Gonzalez JG, Hernandez E, Rosenstock J, Garvey WT, Goldberg RB, Handelsman Y,**

**Jones MR, Abby SL, Lai Y-L, Jin X, Misir S, Nagendran S.** The use of colesevelam HCl for patients with prediabetes and hypercholesterolemia in Colombia and Mexico. *The Latin America Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension, (CODHy)*, Buenos Aires, 3/2010

**Handelsman Y, Rigby SP, Lai Y-L, Nagendran S, Abby SL, Tao B, Jones MR.** Effects of colesevelam HCl (Welchol®), rosiglitazone (Avandia®), or sitagliptin (Januvia®) in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy. *American Association of*

*Clinical Endocrinologists (AACE) Meeting and Clinical Congress*; Houston, Texas; May 2009.  
**Hernandez E, Gonzalez Gonzalez JG, Rosenstock J, Garvey WT, Goldberg RB, Handelsman Y, Jones MR, Abby SL, Lai Y-L, Jin X, Misir S, Nagendran S.** Metformin + colesevelam provides greater glycemic control than metformin alone in patients from Colombia and Mexico. *The Latin*

*America Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension, (CODHy)*, Buenos Aires, Argentina, March 2010.

**Jialal I, Handelsman Y, Fonseca VA, Abby SL, Jones MR.** Concomitant reduction in LDL-C and A1C with colesevelam HCl in patients with type 2 diabetes: a pooled analysis. *68<sup>th</sup> Annual American Diabetes Association (ADA) Scientific Sessions*; San Francisco, California; June 6-10, 2008

**Handelsman Y.** Incretins, the New Paradigm in the Treatment of Diabetes- Clinical Experience. *The 3<sup>rd</sup> Russel Berrie D- Cure Symposium*. October 2007. Tel Aviv, Israel.

## **Other Publications**

**Handelsman Y.** Using Estimated Average Glucose in Diabetes Management- Commentary on ADA 2010 position. *Creatus*. <http://ourcreatus.org>. April 2010

**Bloomgarden Z, Handelsman Y.** Examining the relationship between HbA1c, mortality. *Endocrinology Today*; Editorial: Currie CJ, Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. (*Lancet*. 2010;375:481-9) March 2010

**Handelsman Y, Andress D.** A conversation: Linking CKD and CVD: Nontraditional Risk Factor for CVD in CKD and the Impact of Active Vitamin D Therapy on Survival CKD. An endocrinologist's and nephrologist's perspective. *ASN CKD Communiqué*, Issue #3 October 17, 2007

**Handelsman Y.** Is Obesity Contagious. *Clinical Endocrinology News* September 2007.

**Mechanick JI, Cobin RH, Einhorn D, Handelsman, et al.** AACE/ACE Réaffirmation, 2003 ACE Insulin Resistance Syndrome Position Statèrent [www.AACE.com](http://www.AACE.com) 10/2005

## **Consensus Conferences & Position Statements**

Chair The Early Intervention and Intensive Therapy in T2D and CardioRenalMetabolic Diseases- a Consensus Position 2022

Chair DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases 2021

Pillar Co-Chair & writing committee: AACE/ACE Consensus Conference on CGM	2016
Chair, AACE/ACE Scientific and Clinical Review: Association of SGLT2 Inhibitors and DKA	2015
Member, Writing Committee American College of Cardiology consensus on Metabolic Syndrome	2014-15
Member, American college of cardiology task force LDL: Address the Risk Think Tank	2013,15
Pillar Co-Chair & writing committee: AACE/ACE Consensus Conference on Obesity: Building an Evidence Base for Comprehensive Action	2013
Pillar Co-Chair & writing committee: AACE/ACE Consensus Conference on Glucose monitoring.	2014
Member- AACE Insulin Pump Management Task Force & Writing committee American Association of Clinical Endocrinologists Update Consensus Panel on Insulin Pump Management.	2013-14
Member, Writing Committee and Task Force: AACE Comprehensive Diabetes Management Algorithm	2013
Chair, Writing Committee & AACE Task Force Consensus statement on the state of Diabetes and cancer and its management and Clinical Implication	2013
Chair, Workshop and Writing groups of AACE Consensus statement on the Clinical Approach to the detection of Lipodystrophy	2013
Member, Workshop and Writing Committee The Role of Bromocriptine-QR in the Management of Type 2 Diabetes - Expert Panel Recommendations	2012
Chair, Writing committee and Task Force, Medical Guidelines For Clinical Practice for the Diagnosis and Treatment of Dyslipidemia and Prevention of Atherogenesis 2002 Amended Version – AACE	2011
President, AACE Board, Position Statement on Healthcare Disparities	2011
Diabetes Council Chair, Member- AACE Insulin Pump Management Task Force, Statement By the American Association of Clinical Endocrinologists Consensus Panel on Insulin Pump Management	2010
Diabetes Council Chair, Writing committee and Task Force, Developing a Diabetes Comprehensive Care Plan – AACE	2011
Diabetes Council Chair, AACE Board: AACE/ACE Statement on the use of A1C for the Diagnosis of Diabetes <i>Endocrine Practice</i> March/April 2010; 2: 155-6	2010

Diabetes Council Chair, AACE Board: AACE Position Statement on the Safety of Liraglutide <a href="http://www.AACE.com">www.AACE.com</a>	2010
Member, Writing committee and Task force, Consensus Panel on Type 2 Diabetes Mellitus: Algorithm for Glycemic Control – AACE	2009-10
Chair, Writing Committee, Position Statement Insulin & Cancer – AACE	2009
Co-Chair, Consensus Conference on the “Diagnosis and Management of Pre-Diabetes in the Continuum of Hyperglycemia or When Do the Risks of Diabetes Begin?” – American College Endocrinology	2008
Participant, Improving Inpatient Diabetes Care: A Call to Action Conference American College of Endocrinology	2006
Member, Task Force to Review SMBG Consensus Conference Statement – AACE	2005-06
Co-Chair, Writing Committee, Reaffirmation of the 2003 ACE Insulin Resistance Syndrome (IRS) Position Statement. – ACE & AACE	2005
Member, Writing Committee, “Implementation Conference for ACE Outpatient Diabetes Mellitus Consensus Conference” – ACE & AACE	2005
Member, Writing Committee – Position Statement on Metabolic & Cardiovascular Consequences of Polycystic Ovary Syndrome (PCOS) – AACE	2004
Participant, Consensus Development Conference on Inpatient Diabetes and Metabolic Control – ACE	2004
Co-Chair, The Insulin Resistance Syndrome – Consensus Conference, American Association of Clinical Endocrinologists & American College of Endocrinology. Washington, D.C.	2002

## **Special Reviews**

Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, Nadolsky K, Pessah-Pollack R, Plodkowski R; Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines. American Association Of Clinical Endocrinologists & American College Of Endocrinology Clinical Practice Guidelines For Comprehensive Medical Care Of Patients With Obesity - Executive Summary. *Endocr Pract.* 2016 May 24. PubMed PMID: 27219496.

“Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Hypertension.” American Association of Clinical Endocrinology. *Endocr Pract.* 2006; vol 12, March/April 2006 193

“Medical Guideline for Clinical Practice for the Diagnosis and Management of Thyroid Nodules” American Association of Clinical Endocrinologists and Associazione Medici Endocrinologi *Endocr Pract.* 2006; vol 12, January/February 2006 63

“Assessment and Management of Adult Obesity: A primer for Physicians” American Medical Association, part of the series Roadmaps for clinical practice. Developed in collaboration with the U.S.

Department of Health and Human Services, consists of 10 booklets that offer practical recommendations for addressing adult obesity in the primary care setting. *Published AMA 12 14, 2003*

“Medical guidelines for the clinical use of Dietary Supplements and Nutraceuticals” American Association of Clinical Endocrinologists – AACE nutrition guidelines. *Endocr Pract. 2003;9 417*

”Medical Guidelines for Clinical Practice for the evaluation and treatment of Hyperthyroidism and Hypothyroidism” American Association of Clinical Endocrinologists. *Endocr Pract. 2002;8 457*

### **Reviewer for: (Partial List)**

Journal American College of cardiologists  
Diabetes, Obesity & Metabolism  
Diabetes Care  
Journal of Clinical Endocrinology & Metabolism  
Circulation  
Endocrine Practice  
Expert Opinion on Pharmacotherapy (EOP)  
Oxford University Press  
Mary Ann Liebert, Inc  
Journal of Diabetes  
Thomson Reuters  
Metabolism  
Nature  
On Drugs Metabolism and toxicology  
International journal of Obesity  
JAMA  
Diabetologia  
British Medical Journal

### **Board Certification**

Diplomate Internal Medicine, National Board of Physicians and Surgeons 2017, 2019, 2021, 2023

Diplomate American Board Internal Medicine 1996, 2007

### **Medical Licensure**

Nevada Medical License #7496 1995

California Medical License #A044525 1988

Israeli Medical License #17177 1984

### **Hospital Appointments**

Attending Physician, Providence Cedars-Sinai Tarzana Medical Center,

Tarzana , California.	2020-
Attending Physician, Providence Tarzana Medical Center	2008-2020
Attending Physician, Tarzana Medical Center	1991-2008
Attending Physician (Voluntary Resignation), Sherman Oaks Hospital, CA	1999-02
Attending Physician (Voluntary Resignation), Encino- Medical Center, Encino, California.	1991-09
Attending Physician (Voluntary Resignation), Granada Hills Community Hospital, Granada Hills, California.	1991-97
Attending Physician (Voluntary Resignation), Midway Hospital, Los Angeles, California.	1990-93
Clinical Instructor of Medicine – University of Southern California Medical School, Los Angeles, California.	1988–90

### **Professional Qualifications**

Qualified Medical Examiner (QME).	1991
Radiography X-ray Supervisor and Operator.	1990
D. E. A. Number: <b>BH1514567</b>	1988
American Heart Association - ACLS/BCLS provider.	1985, 1988
Certificate, F.L.E.X examination #53567, California.	1984

### **Disclosures for CME**

**Research grants, consult & speaker honoraria-** Amarin, Amgen, AZ, Bayer, BI, BI-Lilly, BMS, Esperion, Gan & Lee, Gilead, Hamni, Janssen, Lexicon, Lilly, Mankind, Merck, Mylan, New Amsterdam, Novartis, Novo Nordisk, Regeneron, Sanofi, Vertice, Vitrus  
Dr. Handelsman & his immediate family don't have ownership or stocks in any related financial entity.

### **Clinical Research (phase 2, 3, 4)**

High Cholesterol in Subclinical Atherosclerosis at high-risk for ASCVD	2023
Incretins in Diabetes	2023
Catalyst- High Cortisol in Diabetes	2023

Hypertriglyceridemia in Diabetes	2022
Lp(a) in established ASCVD	2022
Severe Hypertriglyceridemia	2021
Prevention of CHF National PI	2019
Diabetes type 2 Long Acting GLP1ra	2019
Diabetes Type 2 & obesity Long Acting GLP1ra	2019
Type 1 DM short Acting insulin	2019
Diabetes Type 1 Insulin Short Acting-	2018
Obesity & Diabetes Type 2	2018
Diabetes Type 2- SGLT2	2018
Diabetes Type 1 Insulin Long Acting- Biosimilar (2 trials)	2018
Diabetes Type 1- SGLT2/1-i	2017
Diabetes Type 1 Insulin Long Acting	2017
Obesity in Diabetes Combination Oral Medications	2017
Diabetes Type 1 Insulin Long Acting	2017
Diabetes Type 2- SGLT2/1-i	2017
Diabetes & CVD- PCSK9i	2016
Non HDL in DM prevent CVD	2016
TGL role in CVD	2016
Type 2 Diabetes in Children	2016
Type 1 Diabetes- Oral medication	2015
Diabetes & CVD- PCSK9i	2015
Diabetes & CVD- Anti coagulation	2014

Type 2 DM combination insulin GLP1	2014
Type 2 DM once weekly GLP1	2014
Type 1 Diabetes, early injectable AB	2014
Type 1 Diabetes- Oral medication	2014
CV Risk Patients- PCSK9	2013
Type 2 DM- implantable GLP1	2013
Type 2 Diabetes Insulin & GLP1	2013
Type 2 Diabetes DPP4 & statin	2013
Type 2 DM once weekly DPP4	2013
High Cholesterol injectable Antibody	2012
Type 2 Diabetes CVD Stable Angina Diabetes	2012
Type 2 Diabetes DPP4 & CVD Safety	2012
Type 2 DM long acting basal Insulin	2012
Type 2 DM DPP4 once weekly	2012
Type 2 Diabetes Insulin & GLP1	2011
Type 2 Diabetes Incretin based therapy	2011
Type 2 Diabetes DPP4 CKD & CVD Safety	2011
Type 2 Diabetes DPP4 Initial Therapy	2011
Type 2 Diabetes- SGLT2 based treatment	2011
Type 2 Diabetes DPP4 Cardiovascular Safety	2010
Type 1 Diabetes- anti antibody	2010
Type 2 Diabetes- anti inflammatory	2010
Type 2 Diabetes DPP4 Cardiovascular Safety	2010
Insulin Based Treatment of Diabetes	2009



Safety of Incretin Based Therapy of Diabetes	2009
Incretin Based Treatment of Diabetes	2009
Management of Pre Diabetes – Glucose & Lipids	2008
Treatment of Diabetes & Lipids	2008
Incretin Based Treatment of Diabetes	2008
Diabetes & Weight loss, New Agent, Combination Therapy	2007
Cholesterol & Diabetes/Pre-Diabetes- Treat or Prevent Diabetes	2007
Diabetes – Insulin and Multiple Oral Medications	2007
Diabetes – New Agent Phase 2b, Mono Therapy	2007
HTN & Metabolic Syndrome	2007
Diabetes – New Agent, Multiple Therapy	2006
Active Vitamin D – The Effect on Kidney Disease Progression	2006-07
Office Based Multiple Clinical Researches - CVD, Lipids, HTN, Diabetes	1993-05
"Acute Arterial Occlusion" - a retrospective study of 145 cases 1980-1983. The Vascular Surgery Department, Shiba Medical Center, Ramat - Gan, Israel. M.D. Thesis – Presented	1984
Israeli Surgical Society – Presented	1985
"Iatrogenic Complications of Vascular Surgeries" A three and a half year Retrospective study. Israeli Surgical Society – Presented	1985

### **Research Interest & Capability**

Diabetes, Obesity, Cholesterol & Dyslipidemia, HTN, Preventive Cardiology, Osteoporosis, PCOS, Thyroid, Bone, NAFLD/NASH  
**Equipment:**, Carotid US (CIMT), Echocardiogram, vascular US, EKG, Stress Test (Treadmill)

### **Teaching-Education**

National and International Speaker - Over 750 CME related lectures:

**Topics:** Diabetes, Pre Diabetes, Cholesterol & Dyslipidemia, HTN, Obesity, Insulin Resistance, CHF Metabolic Syndrome, PCOS, Preventive Cardiology, Osteoporosis, Thyroid, Chronic kidney Disease

### **Sample CME & Sponsoring Providers:**

American College of Physician

Medscape  
American Heart Association  
American College of Cardiology  
American Diabetes Association  
Loyola University Chicago  
University of Florida  
University of Texas Southwestern Medical Center  
Johns Hopkins University School of Medicine  
University of Tennessee College of Pharmacy  
Montefiore Medical Center  
Medical World Conferences  
The Institute for Medical Education  
Antidote  
National Kidney Foundation  
American Association of Clinical Endocrinology  
Cleveland Clinic  
UCLA  
PriMed  
PESI, LLC  
CME Solutions  
Annenberg Center for Health Science at Eisenhower  
Encino Tarzana Regional Medical Center  
National Lipid Association  
Society of Toxicologists and Pathologists  
COHDy Europe  
Vanderbilt University

### **Educational Initiatives – Sample**

The role of the kidney in glucose homeostasis  
Comprehensive management of Diabetes  
AAACE – Incretin National Initiative for Health Care Education  
DPP-IV Inhibition: A New Cornerstone in the Treatment of Type 2 Diabetes  
Apollo Lipid Education Initiative National Faculty  
Thyroid Disorder Education Initiative (TDEI)  
The Medical Education Speaker Network  
Network for Continuing Medical Education  
Diabetes Academy- Improving patient care through Education  
ACE National Diabetes Initiative- Education for the Primary Care Physician  
ADA – PriMed Update on Diabetes

### **Inviting Medical & Academic Centers – Sample**

Peking University, Beijing China  
Hong Kong College of Cardiology Annual Meeting  
Advance Internal Medicine Hong Kong- Annual Meeting  
Cedars Sinai Medical Center- Cardiology department  
UCLA- School of medicine  
Vanderbilt University  
Beer Sheba Medical School, Israel

Barcelona Hospital Center, Spain  
Harbor UCLA  
Hadassah Medical Center, Israel  
City of Hope  
Kings Drew Medical School  
Loma Linda Medical School  
University of Southern California  
Cleveland Clinic Ohio and Florida  
UCLA Pediatric Endocrine Department  
Multiple Hospitals- Grand Round  
Medical Groups & Large Health Systems  
Chinese University of Hong Kong  
Colombia Endocrine and Metabolism Society

### **Inviting Medical Associations – Sample**

Chilean Endocrine and metabolic Association  
Hong Kong College of Cardiology  
Australia Diabetes Society  
Indian diabetes Association  
Korean Diabetes Association  
Brazil Endocrine Association  
Spanish Society of Endocrinology and Nutrition  
Japan Endocrine Society  
Paris NASH French – USA Society  
Philippine Endocrine Society  
Japan Diabetes Society  
Colombia National Endocrine Association  
Israel Endocrine Society  
Costa Rica Endocrine And Nutrition Association  
Philippines AACE  
Endocrine University Mayo Clinic  
National & Pacific Lipid Association  
American Association of Clinical endocrinologists  
Chinese Endocrine Association  
Philippines Diabetes  
Chinese Society of Endocrinology  
Philippines Society of Endocrinology  
Mexico Society of Endocrinology and Nutrition  
American Diabetes Association  
Puerto Rican Society of Endocrinology and Diabetology  
National Lipid Association – Annual Meeting.  
Society of Toxicologic Pathology – Annual Meetings.  
Take care of Your Diabetes (TCOYD)  
Egyptian Society of Endocrinology and Obesity  
D-Cure Russell Burrie Symposium, Israel  
Association of Philippines Physicians of America  
Vascular Biology Working Group  
Philippines College of Physicians, Philippines  
Armenian American Medical Society

Nevada Diabetes Association for Children & Adults  
 The Cypress Foundation Monterey Medical Society  
 Trivalley Indian Medical Association Los Angeles  
 Endocrine Society of Orange County  
 Hong Kong Society of Neurology  
 Hong Kong Federation of Medical Specialties

**Education –Programs (partial not fully updated)**

27 <sup>th</sup> Annual Heart Failure USC, Los Angeles California	2023
Peking University Diabetes Forum, Beijing China	2023
D&CVD 15 Annual European Meeting Tel Aviv, Israel	2023
Diabetes, The Heart and the Kidney making the link- Cairo, Egypt	2022
Chair Symposium AACE Annual Pre Congress , Diabetes & CVD	2019
Annual Paris NASH Symposium	2017
Chair Symposium AACE Annual Pre Congress , Diabetes & CVD	2018
Chair & Program Director, The Heart in Diabetes	2017-
Chair & Program Director, World Congress on Insulin Resistance, Diabetes & CVD	2003-
Chair Symposium 14WCIRDC, Management and Prevention of CVD in Metabolic Syndrome & DM: Focus on PCSK9 Inhibitors	2016
Chair Symposium AACE Annual, LDL-C Reduction in the Patient with Diabetes: How Low Should We Go and How Should We Get There?	2016
Chair Symposium 13WCIRDC, Cardiovascular Disease: The Management of the High Risk Patient in the PCSK9 Inhibitors Era.	2015
Chair Symposium 13WCIRDC, Early Intervention in the Continuum of Hyperglycemia – The Role of Initial Combination Therapy	2015
Chair Symposium ADA Annual, Managing the High Risk Patient – LDL and Beyond: Contemporary and Future Approaches	2015
Chair Symposium ADA Annual, Comprehensive Management of DM: Focus on SGLT2 Inhibitors and Combination Therapy Emerging Concepts of Renal Effects	2015
Chair Symposium ADA Annual, Reducing Residual CVD Risk: Shifting The cholesterol Conversation Beyond Statin Therapy	2015
Chair Symposium AACE Annual, LDL-C Reduction in the High-Risk Patient:	

How Low Should We Go?	2015
Chair Symposium 12WCIRDC, Managing The High Risk Patient LDL and Beyond, Contemporary & Future Approaches	2014
Chair Symposium EASD Annual, Contemporary T2DM Management: Focus on Safety and Efficacy	2014
Co-Chair “AACE-ACC Joint meetings ACC Annual & AACE Annual	2011-2014
Obesity Education Initiative, AACE	2013-2016
Chair, “Diabetes Update” Providence Tarzana Medical Center, Tarzana CA	2012-2016
Chair, “Diabetes Update” Providence Tarzana Medical Center, Tarzana CA	2011
Chair, Obesity Satellite Symposium; “Obesity and Diabetes 2011: The Twin Epidemics” Orlando, FL	2011
Chair, Symposium Type 2 Diabetes: Combination Therapy for Comprehensive Risk Reduction. Orlando, FL	2010
Chair, “Diabetes Update” Providence Tarzana Medical Center, Tarzana CA	2010
Chair, Symposium The Role of Gut Hormone: A Fresh Look At Hormonal Approaches to T2DM, Weight, and Cardiometabolic Risk. Boston, MA	2010
Chair, AACE Diabetes – New Frontier in Clinical Practice. Boston, MA	2010
Chair, Multi Marker Approach to Type 2 Diabetes Risk Consensus Conference Orlando, FL	2010
Chair, Symposium, Type 2 Diabetes – Comprehensive Intervention for CVD Reduction. ADA Annual, New Orleans, LA	2009
Chair, Symposium Obesity & Type 2 Diabetes, AACE Annual, Boston, MA	2009
Chair & Program Director, “Diabetes Update 2009” Providence Tarzana Medical Center, Los Angeles, CA	2009
Chair & Program Director, “Diabetes Update 2008” Tarzana Regional Medical Center, Los Angeles, CA	2008
Chair & Program Director, “Diabetes Update 2007” Encino Tarzana Regional Medical Center, Los Angeles, CA	2007
Lectures, “Metabolic Clinic” A Series of Lectures on Metabolic Disorders Encino Tarzana Regional Medical Center, Los Angeles, CA	2007
Chair & program Director: “Diabetes today and tomorrow” a tribute to Dr. Robert	

Rood, A Series of Lectures Presenting National Leaders in Diabetes in Pregnancy, New Technology and Complete Care	2005
Co-Chair- Diabetes Education Programs for Primary Care Physicians and Allied health, Los Angeles, CA	2004
Program Chair, California Chapter/Western consortium, “American Association of Clinical Endocrinologists 4 <sup>th</sup> Annual Meeting & Symposium”, San Francisco, CA	2004
Course Chair, Director and Founder, “1 <sup>st</sup> Annual World Congress on Insulin Resistance Syndrome”, Universal City, CA	2003
Program Chair, California Chapter/Western consortium, “American Association of Clinical Endocrinologists 3 <sup>rd</sup> Annual Meeting & Symposium”, Century City, CA	2003
Chair, Program Director, “ Insulin Resistance Metabolic Syndrome X: Hypertension, Obesity, Dyslipidemia, Diabetes & the Heart ”, Universal City, CA	2002
Program Chair, California Chapter, AACE 2 <sup>nd</sup> Annual Meeting & Symposium, Las Vegas, NV	2002
Co-Chair, The Insulin Resistance Syndrome – Consensus Conference, AACE/ACE, Washington D.C.	2002
Chair, Program Director, “Women & Menopause” Universal City, CA	2002
Chair, Program Director – “Metabolic- Insulin Resistance – Syndrome: Syndrome X, Diabetes, Hypertension & the Heart”, Woodland Hills, CA	2001
Program Chair, California Chapter, “American Association of Clinical Endocrinologists 1st Annual Meeting & Symposium”, Anaheim, CA	2001
Course Chair, Inaugural Meeting, California Chapter, American Association of Clinical Endocrinologists, San Francisco, CA	2001
Chair, Program Director – “Syndrome X, Diabetes, Obesity, Hypertension & the Heart”, Woodland Hills, CA	2000
Chair, Program Director – “Syndrome X, Diabetes, Obesity & the Heart”, Woodland Hills, CA	1999
Moderator, Monthly Endocrine & Metabolism – Grand Round, Encino Tarzana Medical Center, Tarzana, CA	1998-04
Chair, Founder Program Director, Annual Insulin Resistance Metabolic Syndrome X, Los Angeles, CA	1998-02
Course Chair & Program Director – Endocrine & Metabolic Symposium. A series of CME conferences targeting the Diabetes, Obesity, Thyroid, Women’s Health, Cardiovascular & Osteoporosis, Los Angeles, CA	1998-02

Program Director, Metabolic – Endocrine CME Conferences, the Metabolic Institute for Endocrine Therapeutics, Tarzana, CA	1998-02
Chair, Program Director – “Syndrome X, Diabetes and Beyond” Tarzana, CA	1998
Moderator, Monthly Diabetes Grand Round, Encino Tarzana Medical Center, Tarzana, CA	1994-04
Director of Education, Diabetes Care Center, Encino Tarzana, CA	1994-03
Clinical Instructor of Medicine - University of Southern California Medical School, Los Angeles, CA	1988-90

**National Faculty & Notable CME Lectures** *(partial- not updated since 2014)*

“Contemporary T2DM Management: Focus on Safety and Efficacy” 50th Annual EASD Meetings, Vienna, Austria	2014
Lecture, “Contemporary Approach to Lipid Management & Pipeline of Lipid Medications” 6th Joint Meeting of AACE & AACE Philippine Chapter Manila, Philippines	2014
Lecture, “Endocrinologists in the USA- the Road for Specialty Certification & Recognition” Annual Congress of Chinese Endocrinologist Association (CEA) Xiamen, China	2014
Lecture, “Hyperglycemia and the Potential Role for New Therapies in Type 2 Diabetes Management” AACE 23rd Annual Scientific and Clinical Congress” Las Vegas, NV	2014
Lecture, “Real life Impact of Hypoglycemia Reduction” Diabetes Leadership Summit, Cancun, Mexico	2014
Lecture, “LDL and Beyond: Current and Future Approaches to Cholesterol Management” Providence Tarzana Hospital, Tarzana, CA	2014
Lecture, “Obesity and its Management” Danish Saxenda Investors Meeting Vienna, Austria	2014
Lecture, “Current Medical Therapy and Expectations for New Drugs in Managing the Diabetic Patient” Gilead: Medical Affairs National Meeting San Diego, CA	2014
Lecture, “SGLT2 inhibitors: From Mechanism to Clinical Practice” Janssen International Advisory Board Tel Aviv, Israel	2014

Lecture, “Cancer, Obesity, and Diabetes Risk” AACE 23rd Annual Scientific and Clinical Congress” Las Vegas, NV	2014
Lecture, “Exenatide: Beyond Expectation on Glycemic Control & Weight Loss”	
6th Joint Meeting of AACE & AACE Philippine Chapter Manila, Philippines	2014
Lecture, “Efficacy and Safety of Exenatide Once Weekly Over Five Years” AstraZeneca Asia Area Bydureon Advisory Board, Manila, Philippines	2014
Lecture, “LDL and Beyond: Current and Future Approaches to Cholesterol Management” AACE Endocrine University, Rochester, MN	2014
Lecture, “Treatment Algorithms in T2D: From Theory to Clinical Practice” Diabetes Leadership Summit, Cancun, Mexico	2014
Lecture, “SGLT2 inhibitors: From Mechanism to Clinical Practice” AstraZeneca Lecture Series, Guangzhou, China	2014
Lecture, “2013 AACE New Comprehensive Diabetes Algorithms” 6th Joint Meeting of AACE & AACE Philippine Chapter Manila, Philippines	2014
Lecture, “The Importance of Dyslipidemia in Diabetes: Cholesterol Management and the Role of PCSK9 in Cholesterol Homeostasis” AACE Annual Meetings, Las Vegas, NV	2014
Lecture, “The Role of Basal insulin in patients with T2DM” Basal Insulin Summit, Cancun, Mexico	2014
Lecture, “Exenatide QW vs insulin glargine DURATION 3” AstraZeneca Asia Area Bydureon Advisory Board, Manila, Philippines	2014
Lecture, “Comprehensive Approaches to the Management of Diabetes: The 2013 AACE Diabetes Algorithm” IACC Pri-Med Program, Chicago, IL	2013
Lecture, “The Endocrine Heart” ACC-AACE 3rd Joint Symposium San Francisco, CA	2013
Lecture, “Comprehensive Management of Patients With Type 2 Diabetes: Global Goals for Risk Reduction ”Medscape Education Meeting at AACE 23 <sup>rd</sup> Annual Meetings Las Vegas, NV	2013
Lecture, “New Strategies to the management of Obesity” Providence Tarzana Hospital, Tarzana, CA	2013
Lecture, New Strategies for Obesity Management: Risk Stratification and Long-Term Weight Control” California AACE Annual Meetings, Los Angeles, CA	2013



Lecture, "Type 2 Diabetes Mellitus: Hyperglycemia Pharmacologic Management" 5th Annual Orange County Symposium, Anaheim, CA	2013
Lecture, "Emerging Treatments and Novel Strategies in the Management of Obesity" 29th Annual Rose Conference Minneapolis, MN	2013
Lecture, "Comprehensive Approach to Managing Obesity, Cardiometabolic Risks & Diabetes" IACC Pri-Med Program, Chicago, IL	2013
Lecture, "Comprehensive Approach to the Management of Diabetes" Providence Tarzana Hospital, Tarzana, CA	2013
Lecture, "Emerging Treatments and Novel Strategies in the Management of Obesity" 29th Annual ROSE Conference, Minneapolis, MN	2013
Lecture, "Obesity, Contemporary Approach" 11 <sup>th</sup> WCIRDC, Los Angeles, CA	2013
Lecture, "The 2013 approach to Heart Disease in Diabetes" AACE 22 Annual Scientific & Clinical Congress, Phoenix, AZ	2013
Chair, Workshop on the state of Diabetes, Obesity and cancer, its management and Clinical Implication. AACE/ACE, New York, NY	2012
Chair, Workshop and on the Clinical Approach to the detection of Lipodystrophy AACE/ACE, Santa Monica, CA	2012
Lecture, "Goals and Management of Dyslipidemia-LDL and Beyond" SMNE/AACE Joint Pre-Congress, Leon, Mexico	2012
Lecture, "Diabetes and Cancer", Providence Tarzana Hospital, Tarzana, CA	2012
Lecture, "Diabetes and Genetics" National Lipids Association, San Diego, CA	2012
Lecture "Clinical Implication of Insulin Resistance Metabolic Syndrome" VA Sepulveda Los Angeles, CA	2012
Lecture, "The Role of Incretins in Glucose Homeostasis" AACE Los Angeles	2012
Lecture, "Role of Incretin-based Treatments in the Management of Type 2 Diabetes: Clinical Efficacy and Safety" AACE New York City	2011
Lecture, "Obesity, Diabetes & CVD Contemporary Approach" World Congress on Insulin Resistance Diabetes and CVD	2011
Lecture, "AACE Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan" AACE Annual meeting	2011

Lecture “Post-ACCORD–Is Glycemia a Moving Target? Defining & Individualizing Glucose Targets < 6.5%” American Diabetes association Annual	2011
Lecture “Role of Incretin-based Treatments in the Management of Type 2 Diabetes: Practical Applications” AACE San Francisco	2011
Lecture “Treatment Guidelines and Management of Patients with Type 2 Diabetes” Horizon Portland Oregon	2011
Lecture “Contemporary Goals for the Treatment of Diabetes” Providence Tarzana Hospital	2011
Lecture “Chronic Kidney Disease In Diabetes Mellitus” Annual New Cardiovascular Horizons New Orleans	2011
Lecture “The Metabolic Spectrum of Insulin Resistance- Primary Care Approach to Diagnosis & Management” CV Center Carson City Nevada	2011
Lecture “The Comprehensive approach to Treating Diabetes” Mexican Society of Endocrinology and Nutrition Guadalajara Mexico	2011
Lecture “Clinical Implication of Insulin Resistance Metabolic Syndrome” Puerto Rico Endocrine Society Annual. San Juan Puerto Rico	2011
Lecture “Multi Hormonal Obesity DM & CVD” Nevada AACE Annual	2011
Lecture “The Diabetes Specialist- Comprehensive approach to CV Risk Reduction” AACE Annual	2011
Lecture, “The Metabolic Spectrum of Insulin Resistance” & “The Comprehensive Approach to Treating Diabetes”, The Chinese Endocrinology Society, Shanghai, China	2011
Lecture, “AACE Update in Diabetes Guidelines and Recommendations for Clinical Practice” Philippines College of Physicians, Manila, Philippines	2010
Diabetes – Treatment Goals: Prevent Complications with Comprehensive Control, Orlando, FL	2010
Clinical Highlights from the 2010 AACE Meeting with a Focus on Incretins and Cardiometabolic Risk, San Francisco, CA	2010
The Role of Bile Acid Sequestrants in the Treatment of Type 2 Diabetes Mellitus, Prague, Czech Republic	2010
Type 2 Diabetes – Obesity, Pathophysiology, Diagnosis & Treatment Goals, Los Angeles, CA	2010

AACE Diabetes – New Frontier in Clinical Practice, Boston, MA	2010
The Role of Endocrinologists- A Specialist in the Comprehensive Treatment of Diabetes, Boston, MA	2010
A1C for the Diagnosis of Diabetes and Pre Diabetes, Tarzana, CA	2010
AACE, Diabetes Algorithm for Treating Hyperglycemia, New York, NY	2010
Managing Hypertension & Dyslipidemia in Patients with Diabetes, PriMed, New Orleans, LA	2009
Key Note Address – Current Strategies for the Prevention and Management of Cardiometabolic Risk, PriMed, Pasadena, CA	2009
Managing Hypertension & Dyslipidemia in Patients with Diabetes, PriMed, San Antonio, TX	2009
Diabetic Dyslipidemia – New & Traditional Approaches to Preventing CVD ADA Annual, New Orleans, LA	2009
Cardiovascular Management of Pre Diabetes, AACE Annual, Washington D.C.	2009
Type 2 Diabetes – Management of CV Disease, ASH Annual, San Francisco, CA	2009
Type 2 Diabetes – The Pathophysiology of Insulin Resistance & CVD Managing Lipids, Glucose & HTN to Prevent CV Complications. Modesto, CA	2008
Cost Considerations for Treating the Patient with Type 2 Diabetes	2008
Does Glycemic Control Matter?	2008
Overcoming Barriers to Treatment of the Minority Patient with Type 2 Diabetes Phoenix, AZ	2008
New Understanding in Pathophysiology of Type 2 Diabetes & The Role of Oral Antidiabetic Therapy, California	2008
In Hospital Management of the Patient with Diabetes, Tarzana, CA	2008
Strategies in Treating CV Risk: A Focus on Hyperglycemia and Dyslipidemia, Los Angeles, CA	2008
Managing the Insulin Resistant Patient with Multiple Risk Factors, Seattle, WA	2008
Endocrine Effect of Organ Transplantation, Moderator, Orlando, FL	2008
Diabetes, Treatment with Insulin, Los Angeles, CA	2008
Metabolic Syndrome Pathophysiology & Clinical Presentation, San Francisco CA	2008

Lecture “Cost Considerations for Treating the Patient with Type 2 Diabetes” Honolulu, HI	2007
Lecture “Identifying and Managing the Complications of Type II Diabetes.” Annual Perspectives in Women’s Health, San Diego, CA	2007
Lecture “Cardiovascular Disease in Type 2 Diabetes: From Research to Clinical Practice”, California AACE – Diabetes Day for Primary Care. Fresno, CA	2007
Lecture, “Best Practices for Patients with Type 2 Diabetes Utilizing Thiazolidindiones”, Los Angeles, CA	2007
Lecture, “Current Concepts for Treating the Patient with Type 2 Diabetes: A Thiazolidinediones Update”, PriMed, Phoenix AZ	2007
Lecture, “Improving Patients Care Through Education” Diabetes Academy, Los Angeles, CA	2007
Lecture, “Benefit of Early Aggressive Combination Therapy in Type 2 DM”, Los Angeles, CA	2007
Round Table, “Approach to Developing DM Treatment Guideline”, Tel-Aviv, Israel	2007
Lecture, “Incretins, The New Paradigm in the Treatment of Diabetesity – <i>Clinical Experience</i> ”. 3 <sup>rd</sup> Russell Burrie D-Cure Symposium, Diabetes & Obesity, Tel-Aviv, Israel	2007
Lecture, “Gain Control, Sustain Control”, PriMed, Boston, MA	2007
Workshop, “Clinical Approach to DM as CVD”, 3 <sup>rd</sup> WCIRS, Boston, MA	2007
Lecture, “Insulin Resistance: Is it Clinical”, 5 <sup>th</sup> WCIRS, Boston, MA	2007
Lecture, “Early Detection of Chronic Kidney Disease in Type 2 Diabetes” California AACE – Diabetes Day for Primary Care. Los Angeles, CA	2007
Lecture, “From Combination Therapy to Basal – Prandial Strategies: Practical Insulin Regimens for Patients with Type 2 Diabetes”. Cutting Edge Strategies For Diabetes Care - Making the Connection, Los Angeles Convention Center	2007
Lecture, “Apnea & Other Sleep Disruptions That Affect Diabetes Taking Control of Your Diabetes”, Los Angeles, CA	2007
Lecture, “Enhancing Outcome in Chronic Kidney Disease – Examining the Role of Active Vitamin D Across the Continuum of CKD”, ST. Jude’s Heritage Fullerton, CA	2007
Lecture, “Metabolic Syndrome and Pre Diabetes for the Primary Care Physician. Is it more than the Sum of its Parts?” Overlake/Bellview Hospital – Seattle, WA	2007

Lecture, "A Novel Approach to Cardiometabolic Risk Reduction: Role of the Endocannabinoid System." Valley Hospital, Lancaster, CA	2007
Lecture, "The Many Faces of the Insulin Resistance Syndrome & The Spectrum of Metabolic Risk." Cedars Sinai Medical Center – Los Angeles, CA	2007
Lecture, "Redefining the Healthy Patient: New Outcomes Data in Type 2 Diabetes." PriMed, San Francisco, CA	2007
Chair, "A Mandate for Early Intensive Treatment of Abdominal Obesity and Cardiometabolic Risk: Why Weight?" AACE Annual, Seattle, WA	2007
Lecture, "Proactive Management of Cardiometabolic Risk" AACE Annual, Seattle, WA	2007
Lecture, "Type 2 Diabetes Standards of Care, Pathophysiology & Cardiovascular Risk", California Chapter of AACE Diabetes Day for Primary Care, San Francisco, CA	2007
Lecture, "The Many Faces of Insulin Resistance & Cardiometabolic Risk", 3 <sup>rd</sup> Annual International Summit on Cardiometabolic Risk, Los Angeles, CA	2007
Chair, "Type 2 Diabetes: From Science to Applications for Clinicians", AACE Annual, Chicago, IL	2006
Lecture, "Metabolic Bone Disease in the Diabetic Patient: Therapeutic Options: Past, Present, and Future", UCLA, Los Angeles, CA	2006
Lecture, "Targeting Insulin Resistance for Vascular Protection", Vascular Biology Working Group, San Francisco, CA	2006
Lecture, "Clinical Imperatives for Treating Patients with Diabetes", Vascular Biology Working Group, University of Florida	2006
Lecture, "The Many Faces of Insulin Resistance and the Spectrum of Cardiovascular Risk", Meriter Hospital, Madison, WI	2006
Lecture, "Metabolic Syndrome: Fantasy or Reality?" Nevada Diabetes Association	2006
Lecture, "Insulin Pump" Oxnard Hospital Grand Rounds	2006
Lecture, "Metabolic Clinic- Insulin Treatment" Tarzana Hospital, Tarzana, CA	2006
Lecture, "Diabetes, Hypertension A Comprehensive Approach", Burbank, CA	2006
Lecture, "Insulin Resistance & the Spectrum of Cardiovascular Risk"	
Philippines College of Physicians, Manila, Philippines	2006
Lecture, "The Science Behind the Cardiovascular Effects of Type 2 Diabetes"	

AACE Annual, Chicago, IL	2006
Lecture Series, “Diabetes, Chronic Kidney Disease and Hyperparathyroidism” Johns Hopkins University School of Medicine & The National Kidney Foundation	2005-07
Lecture, “Insulin Resistance and Coronary Artery Disease New Perspective from Vascular Biology”, Chicago, IL	2005
Lecture, “Perspectives on PPAR Agonists in Cardio Protection”, San Francisco, CA	2005
Lecture, “Multifunctional Intervention on Microvascular Outcomes for Diabetes Risk Reduction; Practical Insights and Strategies”, University of Florida	2005
Lecture, “The role of PPAR Agonists in Treating Atherosclerosis” Los Angeles, CA	2005
Lecture, “Metabolic Syndrome, Obesity, and Insulin Resistance”, Cleveland Clinic, Cleveland, OH	2005
Lecture, “Addressing the Dual Defects in Type 2 Diabetes”, A CME Lecture Series	2005
Lecture, “Insulin Resistance – The State of the Syndrome”, 3 <sup>rd</sup> Annual WCIRS San Francisco, CA	2005
Lecture, “Type 2 Diabetes and Hypertension: New Evidence to Manage the Entire Patient” A CME Lecture Series	2005
Lecture, “Emerging Issues and Questions in Hypertension: The Role of ARBs, CCBs and Diuretics”, University of Texas Southwestern Medical Center, Los Angeles, CA	2005
Lecture, “Diabetes – Take Control Earlier”, Orange County Endocrine Society, Orange County, CA	2005
Lecture, “Dyslipidemia and the Role of HDL Cholesterol”, Trivalley Indian Medical Association, Los Angeles, CA	2005
Moderator, “Pathophysiology of Atherogenic Dyslipidemia”, AACE 14 <sup>th</sup> Annual Meeting, Washington, D.C.	2005
Moderator, “Essentials for Succeeding as a Medical Association Leader, “Ethics – The Importance of Integrity in Today’s Workplace”, AACE Leadership Development Conference, Tempe, AZ	2005
Speaker, Diabetes Workshop, “Insulin & Type 2 Meds”, Tarzana, CA	2005
Moderator, Diabetes Workshop, “Hyperglycemia in the ICC, CCU & The Perioperative Patient”, Tarzana, CA	2005
Lecture, “Insulin Resistance – The Syndrome”, 2 <sup>nd</sup> Annual World Congress on the Insulin Resistance Syndrome	2004

Lecture, “The Clinical Challenges and Future Direction – a Call for Action”, 2 <sup>nd</sup> Annual World Congress on the Insulin Resistance Syndrome	2004
Lecture, “Renal Effects of Statin Therapy”, Cedar Sinai Hospital – Los Angeles, CA	2004
Lecture, “Metabolic Syndrome and Schizophrenia”, Los Angeles County Mental Health Clinic – Los Angeles, CA	2004
Lecture, PriMed, “Dyslipidemia of the Metabolic Syndrome” Birmingham, AL	2004
Lecture, “Maintaining Quality of Life in Patients with Schizophrenia” UCLA Medical Center – Los Angeles, CA	2004
Lecture, “Diabetes Care in Ethnic Minorities”, Association of Philippines Physicians of America, Beverly Hills, CA	2004
Lecture, “Metabolic Aspects of Dyslipidemia”, Armenian American Medical Society	2004
Lecture, “Update on Dyslipidemia: Getting to Goal, Concepts and Solution”, City of Hope, Endocrine Grand Round	2004
Lecture Series, “Maintaining Quality of Life in Patients with Schizophrenia”, University of Florida	2004
Lecture, “Type 2 Diabetes; Focus on Insulin Resistance”, Lecture Series	2004
Lecture, “Insulin Resistance –Metabolic- Syndrome, 277.7 A Unified Concept” California AACE Annual, San Francisco, CA	2004
Lecture, “The Clinical Challenges of the Insulin Resistance Syndrome”, 1 <sup>st</sup> Annual World Congress on the Insulin Resistance Syndrome, Los Angeles, CA	2003
Lecture, “Fat, Metformin & Special Populations” 1 <sup>st</sup> annual World Congress on the Insulin Resistance Syndrome, Los Angeles, CA	2003
Lecture, “Contemporary Approach to Improving Quality of Life in Diabetes”, CaAACE /Western Consortium 3 <sup>rd</sup> Annual Meeting, Los Angeles, CA	2003
Chair, Key Note Lecture: “Insulin Resistance & Cardiovascular Disease, Why and How” AACE Annual Meeting”, San Diego, CA	2003
Lecture, “Clinical Management of The Insulin Resistance Metabolic Syndrome”, The Insulin Resistance Metabolic Syndrome X Conference, Los Angeles, CA	2002
Lecture, “Established Treatment of The Insulin Resistance Syndrome”, “AACE/ACE The Insulin Resistance Dysmetabolic Syndrome Consensus Conference”, Washington, D.C.	2002
Lecture, “Osteoporosis in Menopause Prevention vs. Treatment”, “Women & Menopause” Universal City, Los Angeles, CA	2002

Lecture, “The Metabolic Syndrome – Treatment Overview” - “The Metabolic Insulin Resistance Syndrome: Syndrome X, Diabetes, Hypertension & the Heart – 4 <sup>th</sup> Annual.” Woodland Hills, CA	2001
Chair, “Contemporary Approach to Cardiovascular Disease”, “The Polycystic Ovarian Syndrome & Type 2 Diabetes in Children”, “2001 AACE Annual Meeting” San Antonio, TX	2001
Chair, Workshop, “Obesity Diagnosis & treatment”, “2001 AACE Annual Meeting” San Antonio, TX	2001
Lecture, “Treatment of Diabetes – A Comprehensive Approach” – Syndrome X, Diabetes, Obesity, Hypertension & The Heart – 3 <sup>rd</sup> Annual”, Woodland Hills, CA	2000
Lecture, “Type 2 Diabetes – A Practical Approach to Multi-Drug Treatment-Made Simpler” Syndrome X, Diabetes, Obesity & The Heart, vvvWoodland Hills, CA	1999
Chair, Panel Discussion – “Syndrome X in Non Diabetes – Syndrome X, Diabetes and Beyond”, Tarzana, CA	1998

### **Speakers Bureau, Consultant- Present/Past**

Since 1997 has been part of pharmaceutical companies’ educational activities such as speakers’ bureaus, advisory boards and serving as a consultant.

### **Topics:**

Diabetes, Obesity, Lipids, HTN, CardioRenal metabolic diseases, Kidney Disease, CVD, CHF , Osteoporosis, Thyroid, Vitamin D,

### **National & International Speaker & Speakers Bureau**

Abbott, Amylin, AZ, Amilyn-Lilly, Animas, Astra Zeneca, Aventis, ,Biovail, BI, BI-Lilly, Bristol-Myers Squibb, Daiichi Sankyo, Esperion, GlaxoSmith Kline, Janssen, Jones (Monarch/King,) Lilly, Merck, Minimed/Medtronics, Novartis ,Novo Nordisk ,Parke-Davis ,Pfizer ,Proctor & Gamble ,Roche, Sanofi-Aventis, Santarus Takeda, Vivus

### **Consultant**

Abbott, Aegerion, Amarin, Amylin, AstraZeneca, Biovail, BMS, DiaDeux, Eisai, Esperion, Genentech, Gilead, Intarcia, Janssen, Daiichi Sankyo, GlaxoSmithKline, Lexicon Lilly, Liposcience, MiniMed, Merck, Medtronics, Otsuka, Parke-Davis, Pfizer, ResMed, Sankyo, salix, Santarus Takeda, Tethys, Target Tolerx, XOMA, Vivus,

### **Institutional Departments, Committee Memberships & Other Activities**

### **AACE / ACE-**



Chair AACE Lipid & CV Health Disease network	2018-19
IP- President, American College of Endocrinology	2014-15
IP- President, American Association of Clinical Endocrinologists	2012-13
Advisor, American Association of Clinical Endocrinologists Board of Directors	2016-17
Member, AACE Lipid Guideline Committee	2005-16
Member, AACE, Obesity Scientific Committee	2013- 18
Chair, ACE Nomination Committee	2015-16
Chair, AACE Nomination Committee	2015-16
AACE Obesity Educational Program Committee	2014
AACE Nuclear Medicine Endocrine Certifying Board Committee	2014
AACE Education Services Committee	2012-15
Member, Board California Chapter of AACE	2001-18
AACE International Education Academy	2012-15
AACE, Allied Health Education Committee	2012-15
AACE, Council on Education	2013 -15
AACE, Council on Technology	2013
AACE Executive Committee	2007-2016
AACE/ACE- Finance Committee	2008-15
AACE Nominating Committee	2012-17
Chair, AACE Patient Registry Oversight Committee	2013
AACE Industry Education Steering Committee	2012
AACE Primary Care Physician Education committee	2012
Task Force to Review AACE involvement in International Program	2010-
Task Force to explore AACE relationship with medical societies	2010-
Task Force to Evaluate “Diabetes Surgery Summit (DSS)” Consensus Conference	2008-

Chair & member ACE/AACE Award Committee	2010-16
AACE Rapid Response team – IP-President	2010-13
V- President, AACECORP Board of Directors	2012-13
Co-Chair, Corporate Advisory Partners, AACE	2010-11
Chair – Award Committee AACE/ACE	2010-11
Immediate Past Chair – AACE Diabetes Council	2010-11
AACE, Nominating Committee, Ex Officio	2010-11
Task Force to Evaluate AACE administering a credentialing Program For Endocrine PA	2010-11
Member, Corporate Advisory Partners, AACE	2009-11
Chair, AACE Diabetes Guideline Committee	2009-11
AACE, Educational Services Committee	2009-11
Member, Corporate Advisory Partners – AACE	2009-11
AACE, Task Force Insulin Pump Therapy and Management Patient Safety	2009-10
Chair – AACE Diabetes Council	2009-10
AACE, Diabetes Council – Scientific Advisory Group	2009- 12
AACE, Educational Initiative Committee	2009-10
Co-Chair Award Committee, AACE/ACE	2009-10
Vice President & Executive Committee Member, AACE	2009-10
Vice President, AACECORP Board of Directors	2009-10
Chair, National Initiative for Diabetes Education of PCP through AACE chapters	2008-11
Liaison, Amylin Initiative for Obesity and Diabetes	2008-11
Liaison, National Initiative for Compassionate Treatment of Lipodysrophy	2008-11
Member, Steering Committee for Study WEL-411, Daiichi Sankyo	2008-10
Chair, Founder & Advisor, AACE National Initiative – Diabetes Education for Primary Care Providers	2008-10
Member, Diabetes Algorithm Task Force – AACE	2008-10

Member, AACE Adipose Tissue Pathophysiology Scientific Writing Team	2008-10
Chair, Pump Treatment Standard of Care Task Force – AACE	2008-09
Chair Programming – Task Force on the Management of Pre Diabetes and Writing Committee, ACE	2008-09
Secretary & Treasurer, Board of Trustees, ACE	2008-09
Treasurer & Executive Committee Member, AACE	2008-09
Treasurer, AACECORP Board of Directors	2008-09
Chair, Finance Committee – AACE	2008-09
Chair, Finance Committee – ACE	2008-09
Chair, AACE Educational Services Committee – AES	2008-09
Vice Chair, AACE Diabetes Council Committee	2008-09
Advisor, Annual Meeting Clinical Congress Program Committee	2008-09
Member, Diabetes Care Guideline Committee – AACE	2008-09
ACE Funding Development Committee	2009-12
Chair, Education Committee – overseeing: annual meeting, Diabetes Education Programs for Primary Care, Developing – Endocrine Education programs for Primary Care, California Chapter of AACE	2007-11
Member, Diabetes Guideline Committee – AACE	2007-09
Secretary & Executive Committee Member – AACE	2007-08
Secretary, AACECORP Board of Directors	2007-08
Co Chair, Task Force Re MACE Award Criteria – ACE	2007-08
Member, Finance Committee – AACE	2007-08
Member, Insulin Pump Therapy & Management of Patient Safety Task Force – ACE	2007-08
Member, Task Force on the Prevention of Diabetes, Chair Macro-Microvascular Symposium – ACE	2007-08
Reviewer, Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Hypertension – AACE	2006-11
Member, Task Force to Review Diabetes Road Map – AACE	2006-11
Member, Bylaws Review Committee – ACE	2006-09

Member, Task Force ACE/AACE Funding Development – ACE	2006-09
Member, Task Force Diabetes Road Map – AACE	2006-09
Past President & Founder– California Chapter, AACE	2006-08
Member, Endocrine Educational Services Committee – AACE	2006-08
Member, Corporate AACE Partnership Steering Committee – AACE	2006-08
Liaison, to the American Diabetes Association – AACE	2006-07
Member, Search Committee “The First Messenger” Editor – AACE	2006-07
Member, Lipid Guidelines Update Task Force – AACE	2005-11
Member, Diabetes Guideline Revision Committee Update – AACE	2005-07
Member, Annual Meeting Clinical Congress Program Committee – AACE	2005-06
Member, FACE Criteria Task Force – ACE	2005-06
Member, Task Force to Review Sister Society Guidelines for AACE Sponsorship – AACE	2005-06
Alternative Representative to American Diabetes Association – AACE	2005-06
Co-Chair & Founder – Diabetes Education Programs for Primary Care Physicians and Allied Health	2004-11
Trustee – America College of Endocrinologists	2004-06
Member, Nominating Committee – ACE	2004-06
Member at Large, Board of Trustees – ACE	2004-06
Member at Large, Nominating Committee – AACE	2004-05
Member, AACE Joint Collaboration with Healthology re Diabetes Articles – AACE	2004-05
Member, Chapter Steering Committee – AACE	2003-07
Member, Task Force “Endocrine Education for PCP” – AACE	2003-04
Board Member – The American Association of Clinical Endocrinologists	2002–07
Member, Task Force – re: National Board of Medical Examiners (NBME) for Collaborating, A Pilot Study on Diabetes – AACE	2002-03
Vice President & Founder – California Chapter of AACE	2001-05

Chair, Annual Meetings & Chair of the Program and Education Committees – California Chapter of AACE	2001-05
Co-Chair, National Task Force for the Insulin Resistance Syndrome – AACE	2001-03
Member at Large, Nominating Committee – AACE	2001-02
Member, Public and Media Relations Committee – AACE	2001-02
Member, Organization & Planning Committee – AACE	2000-02
Co-Chair, AACE – 2001 10 <sup>th</sup> Annual Meeting” & Program Committee San Antonio, TX	2000-01
Vice President & Founder – Steering Committee, California Chapter – AACE	2000-01
Member, Organization & Operations Committee – AACE	1999-00
Medical Consultant and Board Member, Dynamic Home Care, Los Angeles, CA and Las Vegas, NV	1991-09

### **Pacific Lipid Association**

President elect, Pacific Lipid Association	2016-17
Treasure, Pacific Lipid Association	2015-16
Secretary, Pacific Lipid Association	2014-15
Member, Pacific Lipid Association board of directors	2009-14

### **ETRMC Encino Tarzana Regional Medical Center, Tarzana CA**

Director of the Metabolic and Thyroid Center, ETRMC	2000-02
Member, Continuing Medical Education Committee. ETRMC	2000
Chair, Division of Endocrinology and Metabolism, ETRMC	1998-02
Member, Institutional Review Board, ETRMC	1998-01
Director of Education – The Diabetes Care Center, Encino–Tarzana Medical Center, Tarzana, CA	1994-03
Board Member, Diabetes Care Center, Encino Tarzana Regional Medical Center, Tarzana, CA	1994

### **Other Associations**

Chair, Education Committee, American Thyroid Association	2005-06
Member, Education Committee, American Thyroid Association	2002-05
Member, Scientific Advisory Board for Nutrition Superstores.com, Inc.	1999-00
Member, Resource Panel on Medical Review, Los Angeles County Medical Association	1996-99

### **Professional and Society Memberships**

American Association for Preventive cardiology	2016
The Obesity Society	2014
European Association for Study of Diabetes	2010
National Lipid Association- <i>Fellow</i>	2007
Academy of Thyroidologists	2006
American Thyroid Association	2002
Vascular Biology Working Group	2001
American College of Endocrinology – <i>Fellow</i>	2000
American Association of Clinical Endocrinologists – <i>Fellow</i>	1997
American Diabetes Association	1995
International Atherosclerosis Society	1995
American Israeli Medical Society	1991
Los Angeles County Medical Association	1989
California Medical Association	1988
American College of Physicians - <i>Fellow</i> – 1999	1987
American Medical Association	1986-91, 2002
The North American Menopause Society	1995-01
National Osteoporosis Foundation	1995-00
California Medical House Staff Association	1988-90
American Medical Student Association	1985-89

Israeli Medical Association 1985-92

**Past Professional Positions & Appointments**

Board member, American Society of Preventive Cardiology	2016-19
President, Pacific Lipid Association	2017-18
Trustee, American College of Endocrinology	2017-18
Chair, AACE, Diabetes Scientific Committee	2012- 18
Chair, AACE, Lipid Scientific Committee	2013- 18
Member, AACE Executive Committee	2007- 2016
Co-Chair, Corporate Advisory Partners, AACE	2010-11
Chair, Award committee AACE/ACE	2010-11
Executive Editor, “The Journal of Diabetes and Metabolism- Open Access” OMICS Publishing Group, Stanford, CA	2010-11
Immediate Past chair – AACE Diabetes Council	2010-11
Member, Scientific Advisory Board, Annual World Congress of EndoBolism, Shanghai, China	2010-11
AACE , Nominating Committee, Ex Officio	2010-11
Task Force to Evaluate AACE Administering Credentialing Program for Endocrine PA	2010-11
Chair, AACE Diabetes Guideline Committee	2009-11
AACE, Educational Services Committee	2009-11
AACE , Task Force Insulin Pump Therapy and Management Patient Safety	2009-10
Chair, AACE Diabetes Council	2009-10
AACE, Educational Initiative Committee	2009-10
Co-Chair Award committee AACE/ACE	2009-10
Member, Corporate Advisory Partners, AACE	2009
Chair& Founder, AACE National Initiative– Diabetes Education for Primary Care	2008-10
Member, Diabetes Algorithm Task Force – AACE	2008-10
Member, AACE Adipose Tissue Pathophysiology Scientific Writing Team	2008-10

Chair, Pump Treatment Standard of Care Task Force – AACE	2008-09
Chair Programming – Task Force on the Management of Pre Diabetes and Writing Committee, American College of Endocrinology	2008-09
Vice Chair, AACE Diabetes Council	2008
Clinical Investigator, Westside Arthritis & Metabolism Center (WAMC). Metabolic Disorders, Insulin Resistance, Obesity, HTN. Santa Monica, CA	2007-11
Chair, Education Committee – Overseeing: Annual Meetings, Diabetes Education Programs for Primary Care, Developing Endocrine Education Programs for Primary Care, California Chapter of AACE	2007-09
Member, Diabetes Guideline Committee AACE	2007-09
Secretary & Executive Committee Member, American Association of Clinical Endocrinologists	2007-08
Secretary, AACECORP Board of Directors	2007-08
Member, Task Force Diabetes Road Map – AACE	2006-09
Reviewer, Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Hypertension, American Association of Clinical Endocrinologists	2006
Member, Diabetes Guideline Revision Committee update – AACE	2005-07
Trustee – American College of Endocrinologists	2004-06
President, California Chapter, AACE	2004-06
Chair, Education Committee, American Thyroid Association	2004-05
Founder, Chair & Program Director, “Annual World Congress on the Insulin Resistance Syndrome”. <i>Clinical Manifestation of the Insulin Resistance – Metabolic Syndrome</i> , The Cardiovascular Connection, Los Angeles, CA	2003-08
Chair, Founder and Program Director, “The Annual World Congress On the Insulin Resistance Syndrome” <i>Clinical Manifestation of the Insulin Resistance- Metabolic Syndrome</i> , The Cardiovascular Connection	2003-07
Program Director, “Health Symposium <i>LIVE</i> ” in cooperation with “LA Health News” Magazine and the Metabolic Endocrine Education Foundation, An educational medical lecture series to the public, “Medical Epidemics of the 21 <sup>st</sup> Century” Los Angeles, CA	2003
Board Member – The American Association of Clinical Endocrinologists	2002-07
Co-Chair & Founder, International Committee for Insulin Resistance	2002-07



Co-Chair, 10 <sup>th</sup> Annual Meeting & Congress, AACE, San Antonio, TX	2001
Chair, Division of Endocrinology and Metabolism, Encino-Tarzana Regional Medical Center, Tarzana, CA	1998-02
Member, Institutional Review Board, Encino-Tarzana Medical Center, Tarzana, CA	1998-01
Board Member, Diabetes Care Center, Encino Tarzana Regional Medical Center, Tarzana, CA	1994-11
Medical Consultant, “Yad B`yad – Human Saving Fund”, A Charity Organization, Los Angeles, CA	1991-06
Physician, Internal Medicine, Group Practice, Crestview Medical Group, Granada Hills, CA	1990-91
Medical Director and Administrator, Crestview Medical Group, Granada Hills, CA	1990-91
Physician, Internal Medicine, Group Practice, Family Medical Group of Western Avenue, Los Angeles, CA	1989-91
Clinical Instructor of Medicine – University of Southern California Medical School, Los Angeles, CA	1988-90
Clinical Fellow, Section of Diabetes and Clinical Nutrition, LA County University of Southern California (LAC-USC) Medical Center, Los Angeles, CA	1988-90
Emergency Room, Extensive Experience During Residency, New York, NY	1985-88
Medical Consultant, Insurance Companies, Tel-Aviv, Israel	1983-85
General Practitioner, Private Practice, Tel-Aviv, Israel	1983-85
Director and Developer of Medical Care Centers – A Public Service of the Israeli Medical Association. Tel-Aviv, Israel	1983-84

### **Community Honors and Awards**

Outstanding Commitment to the Community Award, The Jewish Federation of Greater Los Angeles, Los Angeles, CA	1998
Community Service Award – Human Life Saving, Hand to Hand Organization, Los Angeles, CA	1996
County of Los Angeles – “Great Humanitarian Award”. Board of Supervisors Los Angeles County, Los Angeles, CA	1995
THETA ALPHA PHI – National Drama Society Honor Award	1975

DELTA SY OMEGA – National Drama Society Honor Award 1973

### **Military Service**

Medical Officer's Course, Israeli Army 1982

Israeli Army Communication Instructor & Supervisor 1966-69

### **Civic Activities**

Immediate Past President & Founder- Council of Israeli Community, Los Angeles, CA 2005

Education Activities, Power of Prevention, AACE - Series of Medical Lectures on Metabolism to Elementary & Middle School kids 2004

Member, executive committee – CECI 2004-06

President and Founder – The Council of Israeli Community, Los Angeles, CA 2001-05

Founder, Past President and Executive Board Member – “The Israeli Independence Day Festival”, Los Angeles, CA 1990-03

Talk Show Host, Key Note Speaker, Radio Producer and Host, - Creator of “Interview Nights”, A Talk Show – Cultural Program: Musical Artists & Discussions on Current Affairs. Designed to foster relationship of the Israeli, the Jewish and general communities in of Los Angeles with over \$50,000 were raised and contributed to education, cultural and children’s programs.

Los Angeles, CA 1990-08 Founder and Vice President of “Promoting Israel Cultural and Education Fund”. A charity organization Established in 1995 to enhance and strengthen the relationship between the Jewish communities in greater Los Angeles, the Christian Community, and the State of Israel. The fund supports schools and youth movements by creating cultural events and giving grants to individual students or to sponsoring organizations. Los Angeles, CA 1995-05

A Speaker and frequent lecturer on medical topics to charity, social service organizations and the community at large. 1990

Community involvement as committee member, chairman and president such as: Affirmative Action and World Trade Committee, Stockton California; Deprived youth recreation, Tel Aviv, Israel. B’nai B’rith International, “Israel Commission” Young Leadership Development Group, Jewish Federation of Greater Los Angeles. Yad B'yad - Human Saving Fund Board Member, Vice President and Medical Director. Kadima Hebrew Academy Day School, Member-Board of Directors. Member of Advisory Board. Founder and creator of annual Israeli Festival, a community wide event to raise money for education, Los Angeles, CA 1990-03

### **Other Work Experience**

Medical Columnist, "L.A. Health News" – a bi-weekly newspaper Extensive administrative, educational, and cultural experience in the United States and Israel. Performing jobs and holding offices such as: Director of youth centers, cultural clubs and adult education.	2001-04
Director of Social Education for the mentally retarded. Counselor and instructor – Handicapped children and adults. Director, The Israeli Special Olympic Games.	1968-82
Medical columnist, various weekly newspapers: LA News, Shalom LA & Israel Shelanu, Los Angeles, CA	1989-94